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Cryptosporidium is the second leading cause of severe diarrhea and diarrheal-related death in children
worldwide. There are currently no vaccines and the only drug available has low efficacy in
immunocompromised individuals who need it most. As an obligate intracellular parasite, Cryptosporidium
relies heavily on its intestinal epithelial host cell to provide a niche for its growth and survival, but little is
known about how the infected cell responds. We conducted a genome wide CRISPR/Cas9 knockout
screen to discover host genes necessary for Cryptosporidium parvum infection. The most enriched genes
indicate that interferon signaling, glycosaminoglycan (GAG) synthesis, and glycosylphosphatidylinositol
(GPI) anchor biosynthesis are important for susceptibility to C. parvum infection and infection induced
cell death. Our identification of the importance of genes required to produce sulfated GAGs supports
previous research that a C-type lectin on the surface of the parasite binds to heparan sulfate to facilitate
attachment. GPI anchor biosynthesis was also an important determinant of susceptibility to C. parvum
infection. Further investigation revealed a type III interferon response to Cryptosporidium in human host
cells, as well as in mice. Treatment of mice with IFNλ reduced infection burden and protected
immunocompromised mice from severe outcomes, including death, with its effects requiring STAT1
signaling in the enterocyte. Initiation of the type III interferon response was abrogated in the absence of
the pattern recognition receptor TLR3. Overall, we identify new host genes to investigate in the
propagation of the parasite Cryptosporidium, as well as elucidate the upstream events required to initiate
production of IFNλ in response to infection.
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ABSTRACT

HOST REQUIREMENTS FOR CRYPTOSPORIDIUM INFECTION AND THE ROLE OF TYPE III
INTERFERON SIGNALING
Alexis René Gibson
Boris Striepen

Cryptosporidium is the second leading cause of severe diarrhea and diarrhealrelated death in children worldwide. There are currently no vaccines and the only drug
available has low efficacy in immunocompromised individuals who need it most. As an
obligate intracellular parasite, Cryptosporidium relies heavily on its intestinal epithelial host
cell to provide a niche for its growth and survival, but little is known about how the infected
cell responds. We conducted a genome-wide CRISPR/Cas9 knockout screen to discover
host genes necessary for Cryptosporidium parvum infection. The most enriched genes
indicate

that

interferon

signaling,

glycosaminoglycan

(GAG)

synthesis,

and

glycosylphosphatidylinositol (GPI) anchor biosynthesis are important for susceptibility to
C. parvum infection and infection-induced cell death. Our identification of the importance
of genes required to produce sulfated GAGs supports previous research that a C-type
lectin on the surface of the parasite binds to heparan sulfate to facilitate attachment. GPI
anchor biosynthesis was also an important determinant of susceptibility to C. parvum
infection. Further investigation revealed a type III interferon response to Cryptosporidium
in human host cells, as well as in mice. Treatment of mice with IFNλ reduced infection
burden and protected immunocompromised mice from severe outcomes, including death,
with its effects requiring STAT1 signaling in the enterocyte. Initiation of the type III
interferon response was abrogated in the absence of the pattern recognition receptor,
vi

TLR3. Overall, we identify new host genes to investigate in the propagation of the parasite
Cryptosporidium, as well as to elucidate the upstream events required to initiate
production of IFNλ in response to infection.
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CHAPTER 1: INTRODUCTION
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1.1 Cryptosporidium and its epithelial host cell
Cryptosporidium is an obligate intracellular parasite, belonging to the phylum
Apicomplexa with relatives including Plasmodium, Toxoplasma, and Eimeria. At least
twenty species of Cryptosporidium have been identified in human cases (Ryan et al. 2014)
with Cryptosporidium hominis and Cryptosporidium parvum the two species most
commonly causing human infection. Identified in a human patient with enterocolitis for the
first time (Nime et al. 1976), Cryptosporidium was not recognized as a major contributor
to human disease until it was found to be prevalent in HIV/AIDS patients (Blanshard et al.
1992).
Cryptosporidium was first observed in the gastrointestinal tract of naturally infected
mice by Ernest Edward Tyzzer (Tyzzer 1907). Tyzzer went on to characterize the
development of both Cryptosporidium muris and C. parvum (Tyzzer 1910, Tyzzer 1912).
Spread via the fecal-oral route, infection is localized to the distal small intestine but in
some cases, when the immune system is severely compromised, the parasite can also be
found in the epithelium of the biliary tract and the lungs (Vakil et al. 1996, Sponseller et al.
2014, Tam et al. 2021). Outbreaks are most frequently linked to contamination of water
sources with the 1993 Milwaukie outbreak affecting at least 400,000 people being the
largest example in the US (Mac Kenzie et al. 1994). Cryptosporidiosis is characterized by
profuse, watery diarrhea and in healthy individuals, the infection is typically self-limiting
(Current and Garcia 1991).
Within the epithelial cell, Cryptosporidium maintains an intracellular but
extracytoplasmic niche. Multiple elaborated structures are visible at the host-parasite
interface namely, an actin patch, a dense band, a ring-shaped structure, and the feeder
2

organelle. Resembling the actin pedestal of attaching and effacing bacteria,
Cryptosporidium infection induces polymerization of host actin at the base of the
parasitophorous vacuole (PV) (Elliott and Clark 2000). The composition of the dense band
is unknown, but it is localized just above the actin patch and may help to maintain the
extracytoplasmic niche. The ring-shaped structure exists at the intersection of the parasite
plasma membrane and the PV. Another intriguing area of the host-parasite interface is a
highly membranous region at the base of the PV termed the feeder organelle. Believed to
be derived from parasite membranes, its location at the base of the parasite and numerous
membrane folds imply a great capacity for absorption. There is currently no empirical
evidence of host nutrients traversing the PV via the feeder organelle to support this
hypothesis in the field.
The recent identification of Cryptosporidium as the second greatest contributor to
moderate to severe diarrhea in children globally (Kotloff et al. 2013), has reinvigorated the
study of this elusive organism. Development of genetic tools to modify the parasite
(Vinayak et al. 2015) and improved models for animal and tissue culture enabled new
discoveries into the biology of Cryptosporidium outlined below.

1.1.1 Phylogeny and Genetics
Cryptosporidium is an apicomplexan parasite and was initially classified as a
member of Coccidia (which includes Toxoplasma and Eimeria) due to its similar life cycle
featuring an environmentally transmitted spore-like oocyst. However, unlike Coccidia,
Cryptosporidium oocysts sporulate within the host and its PV is maintained in an
extracytoplasmic niche. The peripheral localization of the PV of Cryptosporidium is
reminiscent of the epicellular parasitism of Gregarines which are gastrointestinal parasites
3

of invertebrates. Phylogenetic studies comparing the sequence of ribosomal RNA genes
have provided further molecular evidence that Cryptosporidium is more closely related to
Gregarines than to Coccidia (Carreno et al. 1999, Ryan et al. 2016, Salomaki et al. 2021).
Cryptosporidium represents one of the earliest lineages of Apicomplexa to diverge,
making its biology in many important ways distinct from its much better-studied relatives
Toxoplasma and Plasmodium.
Cryptosporidiosis was initially thought to be caused by a single parasite species.
As the understanding of host specificity grew this was replaced by a multitude of strains
and genotypes and different species, often named based on the animal the parasite was
first isolated from. Cryptosporidium parvum was previously considered to be the most
prominent cause of human infection with two genotypes: genotype 1 was more commonly
found in human infections, while genotype 2 was associated with cattle infections (Peng
et al. 1997). More recently, genotype 1 was reclassified as a separate species,
Cryptosporidium hominis (Morgan-Ryan et al. 2002), while the zoonotically transmissible
genotype 2 retained the name C. parvum. Note that even within C. parvum some
anthropomorphic strains adapted to humans as preferred hosts. Several closely related
species can infect humans in addition to their natural animal host, and several of them are
locally important causes of outbreaks and disease (Šlapeta 2013).
The genomes of both C. hominis and C. parvum have been sequenced and both
have an approximately 9 Mb genome, a 30% GC content, and nearly 4,000 protein-coding
genes (Abrahamsen et al. 2004, Xu et al. 2004). The two predominant causes of human
infections share 97% similarity at the nucleotide level. Cryptosporidium has a reduced
genome requiring it to salvage much of its nutrients from the host cell (Abrahamsen et al.
4

2004). The parasite has an extensive repertoire of transporters to facilitate nutrient uptake.
Cryptosporidium lost the apicoplast, though some nuclear genes encoding apicoplast
targeted proteins are still present (Zhu et al. 2000). Lacking the ability to synthesize fatty
acids de novo and the enzymes to oxidize fatty acids, Cryptosporidium is thought to rely
entirely on glycolysis to generate ATP (Zhu 2004). Differences in the metabolic capabilities
based on whether the species infects the intestine (C. hominis, C. parvum) or the stomach
(C. muris, C. andersoni) have been noted with the species in the upper gastrointestinal
tract possessing the greater capability for aerobic metabolism and a conventional electron
transport chain (Liu et al. 2016). Genes most likely involved in host specificity, as
evidenced by positive selection, appear to be families of secreted proteins in subtelomeric
locations (Baptista et al. 2021). Cryptosporidium also has experienced many horizontal
gene transfers from bacteria making some metabolic pathways attractive targets for drug
development (Sateriale and Striepen 2016).
Cryptosporidium possesses a bacterial-type lactate dehydrogenase (LDH) this
enzyme is thought to be essential as the parasite relies exclusively on glycolysis to
produce ATP. LDH was shown to localize to the parasitophorous vacuole during
intracellular development and chemical inhibition of LDH reduced parasite growth in vitro
(Zhang et al. 2015). Consistent with this observation, transcriptional knockdown of LDH
also led to a decrease in parasite growth (Witola et al. 2017). The gene encoding inosine
monophosphate dehydrogenase (IMPDH) in Cryptosporidium is also the result of a
horizontal gene transfer and was a promising drug target (Umejiego et al. 2008, Sharling
et al. 2010). Surprisingly, loss of the purine synthesis pathway by genetic ablation of
IMPDH, or other members of the guanosine monophosphate synthesis pathway (GMPS,
5

AK, or AT), had no deleterious effects on parasite growth (Pawlowic et al. 2019). While
this weakens the argument for IMPDH directed therapeutics, it provides new insight into
the metabolic capabilities of Cryptosporidium suggesting the existence of a yet
unidentified importer of purine nucleotides.
Its streamlined genome is just one feature that differentiates Cryptosporidium from
relatives such as Toxoplasma and Plasmodium. Next, we discuss the process of entry into
the host cell.

1.1.2 Attachment and Invasion
Apicomplexan parasites are so named for the apical complex which is involved in
motility, attachment, and invasion (Figure 1.1). Motility is characterized as gliding in which
the parasites glide across substrates, this is facilitated by actomyosin machinery named
the glideosome. The inner membrane complex (IMC) is an elaboration of double
membrane structures underlying the plasma membrane in apicomplexans. Myosin is
anchored to the IMC where it pulls along the F-actin “treadmill”. Several secretory events
occur during motility, attachment, and invasion. Micronemes are the first organelle to be
secreted and their contents include membrane-spanning proteins that become inserted
into the parasite plasma membrane. As myosin pulls along the F-actin fiber, microneme
proteins are linked to the filaments on the inside of the membrane, while attaching to the
substrate on the outside. This transmission results in the forward motion of the parasite.
This process begins at the apical pole and translocation occurs until the basal end leaving
behind characteristic trails of proteins previously found on the surface of the parasite
(Tilley and Upton 1994), the trail is the result of the activity of proteases that cleave the
extracellular domains of microneme proteins.
6

Attachment of Cryptosporidium to host cells is mediated by interactions between
parasite lectins and host carbohydrates. Incubation of sporozoites with lectins specific to
glycoconjugates

containing

galactose-N-acetylgalactosamine

(Ga/GalNac)

lectins

inhibited invasion (Joe et al. 1994, Chen and LaRusso 2000). A mucin-like glycoprotein
containing a C-type lectin domain, CpClec, was identified in C. parvum with orthologues
in C. hominis and C. tyzzeri (Bhalchandra et al. 2013). CpClec recombinant protein
competitively inhibited attachment of C. parvum oocysts to HCT-8 cells, incubation with
heparin or heparan sulfate blocked this interaction with the host cells (Ludington and Ward
2016). C. parvum lacking CpClec displayed reduced infections in vitro and in vivo
(Ludington 2016).
Cryptosporidium also encodes members of the thrombospondin related
anonymous protein (TRAP) family which are conserved across Apicomplexa and facilitate
attachment. At least 12 TRAP members have been identified in C. parvum, some are
paralogs likely indicating that they are functionally redundant (Deng et al. 2002). The
structure of TRAP is highly conserved with at least one thrombospondin 1-type repeat, a
proline-rich region, and a transmembrane domain followed by a short cytoplasmic tail
containing a conserved tryptophan. The first TRAP member identified in Cryptosporidium,
TRAP-C1, was shown to localize to the apical end of the sporozoite, it is likely to be
compartmentalized within the micronemes, as in other apicomplexans (Spano et al. 1998).
TRAP proteins were suggested to interact with sulfated proteoglycans but incubation with
heparin does not completely block the binding of Plasmodium TRAP suggesting another
host protein is also bound by TRAP (Akhouri et al. 2008). Attachment of Cryptosporidium
shares many characteristics with other Apicomplexans, but invasion is divergent.
7

The moving junction is a complex of parasite proteins that are integrated into the
host plasma membrane to allow active invasion, essentially the parasites inject their own
receptor. Only one homolog of the well-characterized moving junction is present in
Cryptosporidium and its localization in the neck of rhoptry organelle has been confirmed
(Valentini et al. 2012). The lack of homologs to the key players identified in the invasion
of Plasmodium and Toxoplasma has left the mechanism of invasion for Cryptosporidium
a mystery. Invasion of epithelial cells by Cryptosporidium is active and requires discharge
of its apical organelles and parasite actin (Chen et al. 2004), consistent with other
apicomplexans (Wetzel et al. 2005). From the time of attachment to the transformation to
a trophozoite, invasion of Cryptosporidium takes seven to eight minutes (Guérin et al.
2021). The parasite attaches, contorts into a bent conformation, the host plasma
membrane engulfs the parasite, and then the parasite re-straightens before rounding up
into the trophozoite. Actin polymerization can be visualized immediately following
attachment and coincides with the secretion of the rhoptry contents. Once the parasite is
internalized, the actin polymerization is elaborated to form a pedestal. How the cascade
leading to actin polymerization is initiated is unknown, but it likely involves a parasite
protein that is presented on the surface or injected during invasion.
Live imaging of invasion has provided great insight into this process, but the
proteins involved of both the host and the parasite are still being investigated. Rhoptry
proteins are injected during invasion, some play a role in the process of invasion, while
others are mediators of host modifications. Six rhoptry bulb proteins have been identified
in Cryptosporidium with some being targeted to the interface between parasite and host
and others directed to the apical cytoskeleton (Guérin et al. 2021). Dense granules are
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secreted following rhoptry secretion, these are less characterized in Cryptosporidium and
the role they play in the formation of the PV and modulation of the host cell are currently
unknown in this infection.

Figure 1.1 The sporozoite
Key apical organelles required for motility, attachment, and invasion of Cryptosporidium
sporozoites are diagrammed

1.1.3 Life cycle
Cryptosporidium has a single host life cycle, with both asexual and sexual
development occurring in the same host (Figure 1.2). Upon ingestion of contaminated food
or water, oocysts travel through the digestive tract until they reach the small intestine.
Once in the small intestine, excystation occurs releasing the infective sporozoites.
Excystation is dependent on several factors, notably temperature, pH, and the presence
of bile (Fayer and Leek 1984). Each oocyst contains four sporozoites which go on to
invade the intestinal epithelium. Following invasion, the parasite morphs from the long
slender sporozoite to the rounded trophozoite. Once inside the host cell, the parasite
undergoes asexual replication in which the single parasite will give rise to eight
merozoites. Merogony requires three rounds of nuclear divisions. Cytokinesis occurs only
9

after the final nuclear division. The merozoites will then egress from the host cell and go
on to infect new cells. Egress of Cryptosporidium is dependent on a subtilisin-like serine
protease (SUB1), with knockdown of this transcript resulting in a 95% decrease in
merozoite release (Nava et al. 2019). Drugs that perform well in assays to measure
parasite egress tend to be rapid inhibitors of parasite growth (Jumani et al. 2019).

Figure 1.2 The life cycle
Excystation occurs releasing sporozoites to invade the epithelium. Once inside, the parasite
transforms from the invasive sporozoite to the intracellular trophozoite. Merogony occurs as the
parasites divide their nuclei from 1N to 8N meront. Merogony is thought to occur at least 3 times
prior to sexualization. Following reinvasion of a merozoite either male or female gamonts form. The
males contain 16 microgametes. Fertilization occurs producing a diploid zygote which then
undergoes meiosis. Sporogony occurs within the host prior to release of the new oocyst.
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In tissue culture, the sexual stages begin to be observed at 36 hours post-infection,
indicating that at least three rounds of asexual replication occur prior to sexualization
(Tandel et al. 2019). The sexual stages of Cryptosporidium include macrogamonts, or
females, and microgamonts, or males. Females have a large cytoplasm and a single large
decondensed nucleus. As the producer of all the components of the oocyst wall, females
are filled wall forming bodies containing oocyst wall proteins as well as amylopectin
granules (Spano et al. 1997). Male gamonts contain sixteen gametes with dense bullet
shaped nuclei and an array of microtubules along the length of the nucleus (Ostrovska
and Paperna 1990). Males do not appear to contain many of the apical machinery required
for motility and invasion and lack flagella, so it is unclear how the male gametes move and
make their way to the female gametes once extracellular. The female remains within its
host cell and the male must traverse the membrane of the host, the PV as well as the
plasma membrane of the female gamete for fertilization to occur. Following formation of
the zygote, the only diploid stage of the life cycle, the parasite undergoes meiosis. Next,
sporulation occurs while the parasite remains in the host cell, a key difference between
Cryptosporidium and the Coccidia. The fertilized female produces everything required for
the formation of the sporozoite explaining the observation of antibodies that recognize
apical organelles in sporozoites also cross reacting with structures in the female (Bonnin
et al. 1993, Bonnin et al. 1995). Finally, oocysts are shed into the intestinal lumen where
they can be excreted to transmit the parasite, or autoinfection can occur perpetuating the
cycle in the current host. Thin-walled oocysts have been proposed to be the source of
autoinfection while thick-walled oocysts are shed into the environment (Current and Reese
1986). The oocyst wall contains an outer layer of lipids and an inner layer of proteinaceous
11

components as well as polysaccharide components that remain to be identified (Harris
and Petry 1999, Samuelson et al. 2013).
In tissue culture, parasites can only be propagated for 72 hours and then growth
ceases. Sex was once proposed to be the reason for the lack of continuous culture
observed in cell lines. Sexualization occurs in culture and the development of the entire
life cycle occurs up to the point of gamete fusion, suggesting a lack of fertilization causes
the stall in growth observed after 72 hours in culture (Tandel et al. 2019). If fertilization is
necessary for continuous growth of the parasite, completion of the life cycle is required for
more than just transmission, highlighting a possible key difference between
Cryptosporidium and related parasites including Plasmodium and Toxoplasma.

1.1.4 Host modifications
Cryptosporidium infection leads to numerous changes in its epithelial host cell. The
most striking change visualized is that of the actin patch which begins to form immediately
after the parasite attaches to the host cell and once invasion is complete, the actin patch
remains for the duration of infection. Changes in the host cell may facilitate parasite
invasion, nutrient acquisition, and finally egress of the parasite. Host modifications may
also be necessary to evade the immune system. Some of these host modifications may
be directly initiated by the parasite while others may be unintended consequences of
infection; the differences between the two can be difficult to tease apart.
Many host proteins have been observed at the invasion site immediately following
Cryptosporidium infection. Several of these proteins play a role in invasion and the
establishment of the actin patch (Figure 1.3). Tyrosine phosphorylation and activation of
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phosphoinositide 3-kinase (PI3K) signaling have been noted in a number of cell lines of
different origins, notably human, mouse, and bovine (Forney et al. 1999, Chen et al. 2004).
Inhibitors of PI3K, such as wortmannin, reduce parasite invasion as well as activation of
Frabin, a guanine nucleotide exchange factor. Frabin in turn activates the Rho GTPase,
Cdc42, which accumulates at the site of invasion (Chen et al. 2004). As a key regulator of
actin dynamics, Cdc42 recruits neural Wiskott-Aldrich syndrome (N-WASP) and actinrelated proteins 2/3 (Arp 2/3) culminating in the localized actin polymerization at the
invasion site. Formation of the actin patch likely employs multiple host pathways for the
polymerization of F-actin. The tyrosine kinase, c-Src, was shown to phosphorylate
cortactin, an actin-binding protein, at the invasion site (Chen et al. 2003). Inhibition of Src
kinases or Src homology-2-domain-containing tyrosine phosphatase 2 (Shp-2), an
activator of c-Src, significantly reduces infection of intestinal epithelial cells (Varughese et
al. 2015). The Ca2+ activated cysteine protease, calpain was also shown to be activated
upon invasion and associated with the actin patch suggesting a role for Ca 2+ in invasion
and actin polymerization as well (Perez-Cordon et al. 2011). Taken together, these data
demonstrate that host cytoskeletal dynamics are perturbed by infection and aid in parasite
invasion.
Invasion has also been suggested to be facilitated by the presence of host
aquaporins at the apical membrane. Localized water influx facilitated by the localization of
aquaporin (AQP1) and a sodium/glucose cotransporter (SGLT1) at the site of invasion
was shown to promote membrane protrusions which may play a role in invasion by C.
parvum (Chen et al. 2005). Though localization of another aquaporin, AQP3, to the PV of
Plasmodium liver and blood stages was shown to facilitate nutrient transport and had no
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role in invasion (Posfai et al. 2018). Invasion is thought to occur at microdomains, sites
enriched for sphingolipids and signaling molecules in the plasma membrane (Nelson et
al. 2006). Blocking antibodies to integrins α2/β1 reduced parasite invasion supporting a
role for integrin signaling in attachment and invasion of the parasite (Zhang et al. 2012).
Integrin signaling also occurs at microdomains particularly those enriched in tetraspanins,
a superfamily of four-pass transmembrane proteins (Kummer et al. 2020). Invasion is not
thought to be the result of endocytosis by the host cell as dynamin and clathrin do not
localize to the site of invasion (Chen et al. 2003) consistent with invasion being an active
process by the parasite.

Figure 1.3 Host proteins modified for invasion and actin patch formation in
Cryptosporidium infection
PI3K induced activation of Cdc42 recruits N-WASP and Arp2/3 to induce actin polymerization.
Activation of tyrosine kinase, c-Src, activates cortactin inducing the same N-WASP Arp2/3 actin
polymerization. Integrins α2β1 have been implicated in parasite attachment in addition to host
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GalNac residues. Influx of water and glucose produce localized protrusions of the membrane that
have also been implicated in parasite invasion.

A recent discovery is the delivery of parasite RNAs to the host cell nucleus (Wang
et al. 2016). These long non-coding RNAs could only be detected in the nuclei of actively
infected cells while heat killed parasites or whole-cell lysates of parasites were unable to
induce this effect. Though the mechanism of delivery is unknown, the authors suggest that
the lncRNA can be delivered through a “tunnel-like structure” between the parasite and
the host. Delivery of lncRNA to the host nucleus was dependent upon host HSP70 and its
translocation from the cytoplasm to the nucleus. One of the lncRNA, Cdg7_FLc_0990,
was shown to suppress the transcription of LRP5, SLC7A8, and IL33 (Wang et al. 2017).
The host factors including a transcription repressor, BLIMP-1, and the histone lysine
methyltransferase, G9a, were recruited to the promoter region of these three genes only
upon

nuclear

delivery

of

Cdg7_FLc_0990.

Another

nuclear-targeted

lncRNA,

Cdg7_FLc_1000, was shown to suppress host SMPD3, a gene involved in cell cycle arrest
and apoptosis (Ming et al. 2017). Again, the host G9a/BLIMP-1 machinery was directed
to the promoter of the suppressed gene. Thus, selective delivery of RNAs may represent
a strategy employed by Cryptosporidium to induce transcriptional changes in the host cell.
Cryptosporidium infection also suppresses MAPK signaling in IEC by a currently unknown
mechanism (He et al. 2021), but the suppression of transcript expression may once again
point to lncRNA delivered to the host cell nucleus.
Numerous intracellular pathogens modulate cell death programming in the host
cell to promote their own propagation. Investigation into the role of host cell death during
Cryptosporidium infection has yielded conflicting results. Apoptosis was observed in
infected cells based on nuclear condensation and DNA laddering (Chen et al. 1998, Ojcius
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et al. 1999). Upon treatment with caspase inhibitor, zVAD, there was an apparent increase
in the percent of infected cells, the authors suggested that either apoptosis may be used
by the host to restrict infection or apoptosis may be exploited by the parasite for egress.
The idea of apoptosis as a mechanism for parasite egress was raised by several studies.
With annexin V positivity and active caspase 3 as indicators of apoptosis, it was shown
that only infected cells appeared to be in early apoptotic stages when sorted from their
uninfected bystanders at 24 hours post-infection (Mele et al. 2004). At 48 hours postinfection, both infected and uninfected cells expressed active caspase 3. The observation
of apoptosis primarily in bystanders cells was confirmed in infection of a biliary cell line,
H69 (Chen et al. 2001). Cryptosporidium induced apoptosis was shown to be modulated
by NFκB with expression of a super-repressor of NFκB increasing apoptosis in infected
cultures (McCole et al. 2000). Chemical inhibition of NFκB also increased apoptosis
specifically in the infected cells (Chen et al. 2001). Although infection induces apoptosis,
it has also been shown to inhibit apoptosis induced by chemical agents such a
staurosporine (McCole et al. 2000, Liu et al. 2008). Infection upregulated the expression
of several inhibitors of apoptosis. One inhibitor, survivin, when knocked down led to an
increase in apoptosis and a simultaneous decrease in parasite growth (Liu et al. 2008).
The role of apoptosis during Cryptosporidium infection is convoluted, with studies
concluding that both induction and inhibition of apoptosis to be important for successful
infection. Of note, all these studies of apoptosis were conducted in HCT-8 or H69 cells
which as transformed, immortalized cell lines are less susceptible to programmed cell
death. Future work using primary epithelial cells may shed light on whether apoptosis is
required for Cryptosporidium infection or whether apoptosis controls infection.
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The parasite proteins responsible for modifying the host cell are still being
investigated. Several rhoptry proteins have been identified that are secreted during
invasion. Rop1 interacts with LMO7, a host protein that is involved in the organization of
the actin cytoskeleton (Guérin et al. 2021). The Rop1-LMO7 interaction identifies a new
host protein at the site of the actin patch and genetic studies ablating these genes raise
the possibility of this actin structure as not only being a facilitator of parasite invasion, but
potentially as a factor in host defense. The first characterization of parasite effectors
exported during intracellular replication identified a highly abundant protein of the MEDLE
family that is sent to the host cell cytoplasm (Dumaine et al. 2021). At least one possible
function of this MEDLE protein is the induction of endoplasmic reticulum (ER) stress. This
response has been observed in various transcriptional profiling experiments of cells
infected with Cryptosporidium (Deng et al. 2004, Nikolaev et al. 2020). Dumaine et al.
show that mice lacking a key protein in this pathway, DDIT3/CHOP, are less susceptible
to infection, suggesting a possible benefit to the parasite of this ER stress response.

1.1.5 The virus of Cryptosporidium
Cryptosporidium spp. possess a viral endosymbiont. Extrachromosomal dsRNAs
were found to be present in the cytoplasm of sporozoites (Khramtsov et al. 1997). First
thought to be an atypical picobirnavirus, it was difficult to demonstrate whether this virus
infected the parasite or if it was a co-infection of human patients with diarrhea (Gallimore
et al. 1995, Green et al. 1999). Picobirnaviruses are small, segmented dsRNA viruses
found in fecal samples of many vertebrates and invertebrates as well as in the environment
(Malik et al. 2014, Guajardo-Leiva et al. 2020). The dsRNAs within Cryptosporidium were
notably different from picobirnaviruses with a smaller genome and divergence at the
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nucleotide sequence level (Green et al. 1999). Crude lysates of C. parvum oocysts
exhibited RNA-dependent RNA polymerase activity suggesting that the virus indeed
replicates within the parasite (Khramtsov and Upton 1998). Cryptosporidium parvum virus
1 (CPV1) is now classified in the genus Cryspovirus of the family Partitiviridae (Nibert et
al. 2009). To date, CPV1 is the only partitivirus known to infect a protozoan host, all others
infect fungi and plants.
The virus encodes two gene segments, the large segment is an RNA-dependent
RNA polymerase, and the small segment is the capsid protein; these two dsRNA
segments are separately encapsidated (Ghabrial et al. 2011). The virus is thought to be
transmitted directly during division of the parasites (Khramtsov and Upton 2000). Although
the viral RNA has been detected in the supernatant of infected cultures (Jenkins et al.
2015) it is difficult to know with certainty that this RNA was not due to extracellular
parasites in the media.
The putative sequence of the dsRNA segments has been determined for C.
parvum, C. hominis, C. felis, and C. meleagridis (Leoni et al. 2003, Leoni et al. 2006).
Recently the sequence for C. parvum was updated to correct truncations due to previous
sequencing methods (Vong et al. 2017). Comparisons of CPV1 sequences from multiple
C. parvum isolates are 95.8-99.97% similar. When compared to viruses of other species
such as C. parvum vs C. hominis, the similarity is on the order of 91%. These data suggest
sequencing CPV1 dsRNA segments can be used for genotyping as well as subgenotyping
of species.

18

The virus has also been examined as a tool for diagnostic use. A rapid detection
assay was developed using RT-PCR of dsRNA and a lateral flow detection method
(Kozwich et al. 2000). Use of this rapid detection method identified as little as a single
oocyst in a liter of water. Sequencing of the small segment of CPV1 was able to distinguish
isolates based on the geographic location of the case (Xiao et al. 2001).

By

immunoblotting, antibodies against the capsid protein were shown to detect as few as a
single oocyst (Kniel et al. 2004). RT-PCR directed at the Cryspovirus capsid protein was
able to detect as few as 150 oocysts added directly to water samples providing support
for its potential as a water screening method (de Souza et al. 2019). PCR and antibodybased detection methods showed utility for identification of Cryptosporidium in patient and
environmental samples.
Few studies have examined if the virus has any detectable effects on either the
parasite or the host during infection. In infection experiments, two different C. parvum
isolates were given to calves and the Beltsville isolate, produced 5-fold higher oocyst
shedding than the Iowa isolate (Jenkins et al. 2008). The Beltsville isolate was also shown
to have a 3-fold higher CPV1 copy number. In contrast, CPV copy number had no
association with symptoms in human patients such as diarrhea, vomiting, cough, and fever
(Sharma et al. 2016). Studies of potential associations between parasite viruses and
pathology have produced conflicting results. The most highly studied virus of a protozoan
is the Leishmania RNA virus (LRV1). Leishmania parasites infected with LRV1 were
shown to exacerbate disease severity (Ives et al. 2011). Further work is required to
examine the effects of CPV1 on Cryptosporidium induced intestinal pathology. These
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studies will require tools to eliminate the virus as all known isolates of C. hominis and C.
parvum contain CPV1.
As an obligate intracellular parasite, Cryptosporidium is dependent on the host cell
for survival. To this aim, the parasite employs numerous strategies to modify the host cell
but each interaction with the host is an opportunity to be sensed and controlled. Next, we
explore the methods the host cell employs to defend itself against infection.

1.2 Immunity to Cryptosporidium
The immune response to Cryptosporidium infection relies heavily on the protective
effects of IFNγ and T cells though many additional cell types have a role to play in control
and clearance of this infection. A greater understanding of how the immune system
responds to this infection will enable the development of better treatments and
preventative measures including vaccines.

1.2.1 Innate Immunity
Sensing
Pathogens are recognized by a repertoire of sensors termed pattern recognition
receptors (PRRs) that signal to the cell to mount a response (Li and Wu 2021). PRRs
recognize highly conserved features of microbial infection as well as endogenous ligands
in the improper location in the cell, such as cytosolic DNA. Most PRRs can be classified
based on protein domain homology: Toll-like receptors (TLRs), retinoic acid-inducible
gene-I (RIG-I)-like receptors (RLRs), nucleotide oligomerization domain (NOD)-like
receptors (NLRs), C-type lectin receptors (CLRs), and absent in melanoma-2 (AIM2)-like
receptors (ALRs). TLRs were the first PRRs identified and in humans and mice there are
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10 and 12 TLRs, respectively. TLRs are found on the plasma membrane where they
recognize lipids and proteins while TLRs found in endosomes recognize nucleic acids.
TLR4 localized to the plasma membrane recognizes lipopolysaccharide (LPS) while TLR3,
primarily found in the endosome, recognizes dsRNA. RLRs are cytosolic RNA sensors
that signal through the adaptor protein mitochondrial antiviral signaling (MAVS) to induce
type I and III interferon signaling. NLRs are cytoplasmic PRRs most studied for their roles
in the formation of the inflammasome, as caspase-1/11 dependent protein complex
required for the cleavage of pro-IL-1β and pro-IL-18. Many pathogens are sensed by
multiple PRRs during the course of infection to contribute to innate control.
The increased susceptibility of mice lacking MyD88 suggested a TLR recognizes
Cryptosporidium (Rogers et al. 2006). Absence of MyD88 in combination with blockade of
IFNγ further increased susceptibility indicating that the result of TLR recognition is not
entirely dependent on IFNγ. TLR2 and TLR4 localize to the site of invasion following
infection of biliary epithelial cells (Chen et al. 2005). Downstream of TLR activation, IRAK,
p-38 MAPK, and NFκB p-65 are activated following infection. This work also showed
MyD88 deficiency to increase infection in vitro indicating that TLR activation is important
to control the parasite within the epithelial cell. Cryptosporidium infection downregulates
microRNAs, miR-98 and let-7, which in turn de-represses members of the suppressors of
cytokine signaling (SOCS) family of proteins (Chen et al. 2007, Hu et al. 2009, Hu et al.
2010). Both SOCS4 and (cytokine-inducible SH2-containing protein) CIS were
upregulated upon infection, and this was dependent on TLR4, miR-98, and let-7.
Expression of SOCS4 also decreased the phosphorylation of STAT1, STAT3 and STAT6
observed upon infection. TLR4 activation following Cryptosporidium infection has been
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shown to induce nitric oxide production. This was shown to be dependent on mirR-27b
stabilizing mRNA of inducible nitric oxide synthase (iNOS) (Zhou et al. 2012). A host
lncRNA induced by C. parvum activation of TLR4 promotes the antiparasitic effects of
IFNγ in epithelial cells (Gong et al. 2021). It has also been suggested that TLR4 activation
is a possible mechanism for the greater burden of Cryptosporidium in HIV patients. HIV
Tat protein downregulates TLR4 expression in cholangiocytes, and cells transfected with
Tat alone had higher parasite burdens (O’Hara et al. 2009).
TLR4 was shown to be important in a mouse model of biliary cryptosporidiosis.
Mice lacking TLR4 experienced a higher parasite burden and prolonged infections of at
least 4 weeks, compared to 2-3 weeks for wild type mice (O'Hara et al. 2011). TLR4
deficient mice also had increased liver pathology and increased serum concentrations of
liver enzymes indicative of damage to the liver induced by infection. A mouse model of
malnourishment also found that TLR4 may play a role in increased susceptibility of
malnourished animals to cryptosporidiosis (Costa et al. 2011). TLR2 and TLR4 were
upregulated in malnourished mice prior to infection and downregulated following infection.
SNPs in the promoter of TLR4 are also associated with increased susceptibility in children
(Begum Liakath et al. 2021). TLR4 clearly plays a role in Cryptosporidium infection but the
microbiome has not been ruled out as the source of TLR4 activation.
Recently, it was discovered that an NLRP6 inflammasome is responsible for the
epithelial-derived IL-18 secretion observed in previous work (Sateriale et al. 2021). The
Cryptosporidium associated molecular pattern recognized by NLRP6 has not been
identified yet, but it was shown that the increase in susceptibility in inflammasome deficient
mice was independent of the presence of the microbiome and therefore likely
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Cryptosporidium specific. Other sensors of Cryptosporidium infection remain to be
determined.
Epithelial cells
Cryptosporidium exclusively infects epithelial cells therefore the initial responses
to infection occur within these cells. Epithelial cells are known to secrete a number of
cytokines and chemokines in response to Cryptosporidium infection including IL-18,
RANTES, CXCL1, IL-8, CCL20, MCP-1, MP2α, KC, TGFβ as well as type I and III
interferons (Laurent et al. 1997, Maillot et al. 2000, Lacroix-Lamandé et al. 2002, Barakat
et al. 2009, Guesdon et al. 2015, Ferguson et al. 2019). These epithelial-derived cytokines
may act directly on the infected host cells or allow for and enhance the recruitment and
activation of immune cells. CCL20 displayed anti-cryptosporidial activity when given orally
and its effects did not require immune cell infiltration, IFNγ, or the microbiome (Guesdon
et al. 2015) suggesting this epithelial-derived chemokine acts on the enterocytes.
Epithelial cells increase transcript and protein levels of IL-18 upon treatment with
C. parvum even with heat-killed oocysts (McDonald et al. 2006). Treatment of intestinal
epithelial cell lines with IL-18 inhibited parasite growth possibly through the induction of
anti-microbial peptides. IL-18 is secreted following activation of the inflammasome, in line
with that inflammasome components Caspase 1 and adaptor protein, Asc, were shown to
be important for susceptibility to Cryptosporidium infection (McNair et al. 2018).
IFNγ is absolutely required for both control and clearance of Cryptosporidium
infection. Loss of STAT1 exclusively in the enterocyte lineage phenocopies Ifng -/- mice
indicating that IFNγ acts on the infected epithelium (Gullicksrud et al. 2021). Human
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intestinal epithelial cell lines when pretreated with IFNγ have been shown to reduce
parasite infection (Pollok et al. 2001). This effect was shown to be due to a reduction in
invasion following pretreatment and it was not due to nitric oxide synthase activity. Direct
effects on the epithelial cell also do not appear to be due to the action of indoleamine 2,3
dioxygenase (IDO) as the inhibitory effects of IFNγ could not be rescued with the addition
of tryptophan (Pollok et al. 2001, Choudhry et al. 2009). In agreement with these data,
infection of mice lacking IDO does not lead to an increase in susceptibility (Gullicksrud et
al. 2021). Interferons produced by epithelial cells have also been explored for their role in
infection. Type I interferons were upregulated in response to C. parvum exposure in both
epithelial cells and DCs (Barakat et al. 2009). Treatment of neonatal mice with antibodies
against IFNα/β led to increased susceptibility. Enterocytes become less responsive to type
I IFNs with age and the epithelium responds almost exclusively to type III interferon, IFNλ
(Lin et al. 2016). IFNλ is upregulated in response to infection in both a neonatal piglet and
a neonatal mouse model of infection. Antibody blockade of IFNλ led to increased
susceptibility and a mild increase in pathology. This study found that IFNλ could inhibit
parasite invasion and abrogate the parasite-induced loss of transepithelial resistance
(TEER).
Epithelial cells express MHC class II and may have the ability to process and
present antigen (Hershberg and Mayer 2000). Expression of MHCII was reduced
specifically on cells infected with Cryptosporidium suggesting a potential mechanism of
immune evasion employed by the parasite (Sateriale et al. 2019). There is currently no
evidence indicating the IEC as a major antigen-presenting cell during Cryptosporidium
infection.
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Neutrophils
One of the earliest observations of pathology in response to Cryptosporidium
infection was the pronounced recruitment of neutrophils observed in infected intestinal
sections (Tzipori 1988). Chemokines, containing the glutamic acid-leucine-arginine
(ELR+) motif are potent attractants of neutrophils (Sadik et al. 2011). Of this family, 5
members have been indicated to be increased in expression or secreted from cultures or
intestinal sections infected with Cryptosporidium, these include IL-8, KC, IP-10, MIP-2,
and LIX (Laurent et al. 1997, Maillot et al. 2000, Lacroix-Lamandé et al. 2002). The
induction of LIX, KC, and MIP-2 was heightened in the absence of IFNγ where the infection
is exacerbated suggesting that neutrophil recruitment is not important for control of
Cryptosporidium infection (Lacroix-Lamandé et al. 2002). In contrast, neutrophil
extracellular trap (NET) formation was shown to trap parasites and prevent the invasion
of epithelial cells following incubation with neutrophils (Muñoz-Caro et al. 2015). Exposure
of neutrophils to C. parvum also led to a significant increase in the expression of CXCL8
(IL-8), TNFα, GM-CSF, and IL-6. The authors suggest that NETosis could play a major
role in parasite control and that lysis of host cells exposes the parasite to luminal PMNs.
While NETosis offers a plausible mechanism, this work was performed entirely in vitro.
Whether this mechanism plays a major role in vivo, remains to be determined.
Macrophages
Macrophages are a tissue-resident cell type that can present antigen and produce
cytokines to promote inflammation or repair depending on the phenotype of the
macrophage. A role for macrophages in Cryptosporidium infection could only be identified
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after removal of several of the key components of the immune response. Depletion of
macrophages in Rag-/-Il2rg-/- mice, lacking functional B and T cells as well as NK cells, led
to an increase in oocyst shedding as well as a loss of IFNγ expression in these mice
(Choudhry et al. 2012). SCIDbg mice, also lacking functional B and T cells as well as NK
cells, were further depleted of macrophages and polymorphonuclear cells (largely
neutrophils).

These

mice

termed

SCIDbgMN

became

acutely

infected

with

Cryptosporidium and died within 16 days of infection while the parental SCIDbg mice
survived and developed chronic infections (Takeuchi et al. 2008). This acute lethality could
be abrogated by transferring macrophages from mice previously infected with C. parvum
to SCIDbgMN mice or macrophages that had been incubated with PMN from infected
mice. Macrophages are unlikely to be a primary mechanism of control of Cryptosporidium,
but they can partially compensate for loss of other innate immune cells.
Dendritic Cells
Dendritic cells (DCs) play important roles in the sensing and control of mucosal
pathogens. In the intestinal mucosa, DCs are distributed throughout the intestinal lamina
propria, the gut-associated lymphoid tissues, including Peyer's patches and smaller
lymphoid aggregates, as well as in the mesenteric lymph nodes. In the small intestine,
CD103+ CD11b+ DCs are the predominant subset found (Denning et al. 2011). As
professional antigen-presenting cells, the role of DCs role in the development of antigenspecific T cell immunity during Cryptosporidium should be explored.
DC attractant chemokines CCL2, CCL3, CCL4, CCL5, CCL7, and CCL20 are
released in the intestine following Cryptosporidium infection (Auray et al. 2007). CD11c
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DCs were the predominant population observed to be recruited in the infected ileum of
neonates, this recruitment was decreased in infection of Ifng-/- mice. The mesenteric lymph
nodes of infected mice showed an increase in total cells and CD11c+CD11b+ cells were
the predominant population. These DCs showed an increase in surface expression of
CD40, CD86, and MHC II indicating that they were in an activated state. C. parvum antigen
can be found within DCs that have migrated to the mesenteric lymph node (Ponnuraj and
Hayward 2001). Murine and human DCs exposed to solubilized Cryptosporidium antigen
or recombinant antigen-induced the expression of IL-12p70 in a MyD88-dependent
manner (Bedi and Mead 2012). DCs exposed to C. parvum or solubilized antigen have
also been shown to increase expression of type I IFNs, IFNα, and IFNβ (Barakat et al.
2009). During Cryptosporidium infection of neonates, CD103+ DC are recruited to the site
of infection (Lantier et al. 2013). Depletion of CD11c+ cells led to an increase in oocysts
in the intestines of infected mice, suggesting that CD11c+ cells mediate control of parasite
burden. Expansion of CD103+ DCs using Flt3-L injections reduced the infection burden in
wild type mice but had no effect in IL12p40 -/-. Loss of CXCR3 led to an increase in infection
and a decrease in recruitment of CD103+ DCs, similar results were observed in the
absence of IFNγ. CD103+ DCs also produce IL-12p40 and IFNγ. Both neonate and adult
Batf3-/- mice show an early increase in susceptibility to C. parvum infection (Potiron et al.
2018). CD103- CD11b+ DCs are expanded in response to C. parvum infection of Batf3-/but CD103- DCs are shown to make less IL-12p40 suggesting an explanation for the lack
of parasite control in the Batf3 -/-. The expansion and recruitment of DCs in response to
Cryptosporidium infection and their role in producing IL-12 which promotes IFNγ
production is critical to control.
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NK cells/ILCs
Natural killer (NK) cells are an important innate source of IFNγ in bacterial, viral,
and parasitic infections. Splenocytes stimulated with either C. muris or C. parvum have
been shown to induce production of IFNγ (Chen et al. 1993, McDonald et al. 2000). These
results were extended to show that when NK cells were specifically depleted using antiasialo GM1, IFNγ concentration decreased with increasing concentrations of antibody
(McDonald et al. 2000). NK cell activity examined solely in the spleen of mice did not
reveal a role for NK cells in infection (Rohlman et al. 1993). NK cells treated with
physiological concentrations of IL-15 induced cytoxicity of infected HCT-8 (Dann et al.
2005). Host cell lysis was shown to be the consequence of CD3 -CD16+CD56+ (NK cells).
The role of NK cells has also been evaluated by comparing infection of Rag -/-, lacking B
and T cells, to Rag-\- Il2rg-/-, which also lack NK cells. Infections of mice that also lacked
NK cells resulted in higher oocyst shedding and mice succumbed to infection (Barakat et
al. 2009). Interestingly these mice still produced IFNγ in response to infection indicating a
previously unknown source of gamma. Depletion of NK.p46+NK1.1+ NK cells did not lead
to an increase of infection and IL-15-/- mice also did not show an increase in infection
burden (Lantier et al. 2013).
Work from our group has shown that innate lymphoid cells (ILC), specifically ILC1s,
are a major source of IFNγ production during early Cryptosporidium infection (Gullicksrud
et al. 2021). Of the ILC subset expressing Ifng, 80% of those cells expressed the
transcription factor T-bet, identifying them as ILC1s. This work does not negate the studies
of NK cells but is strengthened by the recent work characterizing the NK/ILC subsets. IFNγ
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made by ILC1s acts on the intestinal epithelium to control Cryptosporidium early in
infection.

1.2.2 Adaptive Immunity
B cells
The role of B cells during Cryptosporidium infection has been assessed by the
presence of antigen-specific antibodies to proteins expressed on the surface of the
parasite (Tarazona et al. 1997). A 20-kDa antigen was shown to be immunodominant in
response to Cryptosporidium infection of humans, calves, and horses (Mead et al. 1988).
Human infection studies have shown that there are IgG responses to immunodominant
antigens including glycoproteins gp15 and gp40 (Ajjampur et al. 2011), antigens of 17kDa
(Cp23), 27kDA, and 15kDa (Moss et al. 1998). Although antibody responses occur, B cells
are largely thought to be dispensable for control and clearance of Cryptosporidium (TaghiKilani et al. 1990, Sateriale et al. 2019).
Feeding calves hyperimmune bovine colostrum was partially protective, shortening
the duration of diarrhea and the duration of detectable oocyst shedding (Fayer et al. 1989).
Consistently, feeding neonatal mice with a cocktail of monoclonal antibodies to surface
sporozoite antigens did not prevent infection but parasite load was decreased in the
treated group (Mead et al. 1988). Treatment of an immunocompromised child with
hyperimmune bovine colostrum led to remission of cryptosporidiosis but there was
recrudescence and the patient returned with biliary cryptosporidiosis (Tzipori et al. 1986).
HIV-positive patients with chronic cryptosporidiosis generally have highly elevated levels
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of IgA but cannot control infection, again suggesting again that humoral immunity is not
sufficient (Cozon et al. 1994). Patients with HIV compared to healthy controls showed no
difference in serum IgG and IgA responses to Cryptosporidium infection and the presence
of antibodies did not correlate with severity of symptoms (Kaushik et al. 2009).
While humoral immunity is not sufficient to induce parasite control, it has been
shown to represent a correlate of protection. Prior Cryptosporidium infection or vaccination
is partially protective against a subsequent challenge infection (Checkley et al. 2015).
Fecal IgA against Cp23 was correlated with a delay to subsequent Cryptosporidium
infection (Steiner et al. 2019). High levels of fecal IgA against Cp23 correlate with a delay
in reinfection and abrogation of growth faltering at three years of age (Kabir et al. 2021).
Taken together, humoral responses and treatment with parasite-specific antibodies may
provide some protection during infection though the real advantage of the study of
antibody responses may be in the power to define correlates of protection to future
Cryptosporidium infection.
T cells
The crucial role of T cells in protection during Cryptosporidium infection is apparent
in the high burden of cryptosporidiosis in HIV/AIDS patients. T cells produce critical
cytokines, such as IFNγ, and other functions in the clearance of Cryptosporidium infection
continue to be explored.
Athymic nude mice have protracted infections with C. parvum characterized by
diarrhea and occasionally death (Heine et al. 1984). Severe combined immunodeficiency
(SCID) mice had infections lasting more than 100 days but giving donor spleen cells
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reduced fecal oocyst shedding and shortened the duration of infection (McDonald et al.
1992). Importantly antibody depletion of T cells from the donor splenocytes led to a loss
of protection, again emphasizing the role of T cells in protection. Antibody-mediated
depletion of CD4+ and CD8+ cells in BALB/c mice showed the importance of CD4+ T cells
but also the combined depletion of both led to the greatest increase in oocyst shedding
suggesting a cooperative role for both T cell subsets (Ungar et al. 1991). Mice lacking
MHC I showed no increased susceptibility while mice deficient in MHC II were still infected
up to 8 weeks post-infection (Aguirre et al. 1994). A cohort study done in Bangladeshi
children found an association between HLA-DQB1 *0301 and asymptomatic infection
with Cryptosporidium in addition to an association with the HLA class I B*15 allele,
suggesting that both CD4+ and CD8+ T cell responses are important for parasite control
(Kirkpatrick et al. 2008).
These studies suggest that T cells are needed primarily for clearance rather than
early control of the parasite. In neonates, no requirement for CD4+ T cells was found
during the acute stage of the infection and no expansion of T cells was observed in wildtype mice that cleared the infection (Korbel et al. 2011). Still, as early as 24 hours postinfection, IFNγ can be detected in the intestines of infected mice with intraepithelial
lymphocytes (IELs) identified as TCR αβ+ CD8+ T cells at least one source at this early
timepoint (Leav et al. 2005). T cells are also required for the memory response to infection
with Rag-/- mice being unable to demonstrate protection following vaccination (Sateriale et
al. 2019).
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Primary immunodeficiencies predispose humans to cryptosporidiosis
Cryptosporidium was one of the original AIDS-defining illnesses. The severity of
cryptosporidiosis is highly correlated with lower CD4+ T cell counts and antiretroviral
therapy is an effective treatment resulting in immune mediate clearance of the parasite in
HIV-positive individuals (Blanshard et al. 1992). Patients with a variety of
immunodeficiencies affecting the adaptive immune cell compartment experience
increased susceptibility to Cryptosporidium infection. Immunodeficiencies that predispose
patients to cryptosporidiosis provide insight into the critical components of immunity
against Cryptosporidium.
X-linked hyper IgM syndrome is a rare genetic disorder caused by mutations in
CD40 ligand, a glycoprotein expressed mainly on the surface of activated CD4+ T cells
(Noelle et al. 1992). This syndrome is characterized by reduced serum levels of IgG, IgA,
and IgE but elevated levels of IgM (Notarangelo et al. 1992). Hyper IgM syndrome is also
associated with defects in CD4+ T cell activation, and in mouse models, antibodies against
CD40L prevent the activation of antigen-specific T cells (Roy et al. 1995). The defective T
cells of Hyper IgM patients likely also have a decreased ability to activate DCs as these
cells express high levels of CD40 and are activated by co-culture for CD40L (Caux et al.
1994). Hyper IgM syndrome has been associated with Cryptosporidium infection and in
particular biliary involvement and cholangiopathies due to Cryptosporidium (Levy et al.
1997). Up to 63% of patients with primary immunodeficiencies reported having sclerosing
cholangitis were PCR positive for Cryptosporidium (McLauchlin et al. 2003, Al-Saud et al.
2013).
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Two brothers with Hyper IgM were cured of recurrent Cryptosporidium infection
with cholangitis following bone marrow transplantation (Dimicoli et al. 2003).
Hematopoietic stem cell transfer was effective in eliminating Cryptosporidium infection in
four patients with immunodeficiencies including CD40 ligand deficiencies and WiskottAldrich syndrome (Hadžić et al. 2019). Treatment of a separate set of brothers with Hyper
IgM with an agonist of CD40 reduced but did not eliminate Cryptosporidium infection (Fan
et al. 2012). Bone marrow transplantation can provide improvements but does not always
produce a cure.
MHC class II deficiency, or bare lymphocyte syndrome, is characterized by
defective maturation and activation of CD4+ T cells (Masternak et al. 2000). A study in
Tunisia of five children with primary immune deficiencies showed all five children had
cryptosporidiosis and each was diagnosed with MHC II deficiency (Ben Abda et al. 2011).
In another study, 34% of these patients were positive for Cryptosporidium and most
developed progressive liver failure (Ouederni et al. 2011). MHC II deficiency is highly lethal
and hematopoietic stem cell transfer is the only treatment to delay mortality, but it is most
effective early in life (Saleem et al. 2000, Picard and Fischer 2010).
Mannose-binding lectin (MBL) is a component of the innate immune response, and
its activation triggers the complement pathway. Serum levels of MBL vary across the
population but generally higher levels are associated with protection against many
pathogens of bacterial, viral, and parasitic origin. MBL has been shown to bind directly to
several pathogens, including Cryptosporidium (Kelly et al. 2000). Serum MBL levels were
significantly lower in children with cryptosporidiosis than in healthy controls (Kirkpatrick et
al. 2006). A study of nearly 300 preschool-age children in Bangladesh found a significant
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association between symptomatic Cryptosporidium and lower serum MBL due to a single
nucleotide polymorphism (SNP) in exon 1 (Carmolli et al. 2009). SNPs in the promoter
region of MBL2 were strongly associated with multiple Cryptosporidium infections. MBL
also plays a role in cryptosporidiosis in AIDS patients. Being either homozygous or
heterozygous for MBL mutations increased the risk of cryptosporidiosis in patients with
AIDS despite having a modest and not significant effect on the serum concentration (Kelly
et al. 2000).
Other primary immunodeficiencies that have reported cryptosporidiosis include
hypogammaglobulinemia, selective IgA deficiency, an immunodeficiency in TCRαβT cells,
and IL-21R deficiency, (Lasser et al. 1979, Jacyna et al. 1990, Morgan et al. 2011, Kotlarz
et al. 2013). These deficiencies are likely so rare that few reports exist or susceptibility to
Cryptosporidium infection is not drastically increased in these conditions.
Studying the immune response to Cryptosporidium is crucial to the development
of therapeutic and preventative strategies, especially vaccines, and studies of acquired
immunity demonstrate that protection can be achieved.

1.3 Public Health Importance of Cryptosporidium
1.3.1 Disease Burden
Infectious diseases account for 64% of deaths in children under the age of five,
11% of deaths are due specifically to diarrheal disease (Liu et al. 2012). Cryptosporidium
can be detected in the feces of 15-25% of children with diarrhea (Tumwine et al. 2003,
Samie et al. 2006, Ajjampur et al. 2008). Young age is highly associated with risk of
infection. Children under the age of two carry the greatest burden of infection (Ajjampur et
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al. 2010). Cryptosporidiosis is particularly characterized by prolonged diarrhea (7-14 days)
and persistent diarrhea (> 14 days) (Lima et al. 2000, Moore et al. 2010). Infection with
Cryptosporidium is more highly associated with morbidity and mortality than other causes
of diarrheal disease (Khan et al. 2004).
The Global Enteric Multicenter Study (GEMS) was a three-year study across seven
sites in Africa and Asia designed to determine the burden and causative agents of
pediatric diarrheal disease (Kotloff et al. 2013). This study identified Cryptosporidium as
the second leading cause of diarrheal disease in infants. Into the second year of life cases
attributed to Cryptosporidium persisted but at a lower level. Upon follow-up 2-3 months
after a diarrheal episode, the risk of mortality was greater in cases where Cryptosporidium
had been detected. The significant contribution of Cryptosporidium persisted regardless
of HIV prevalence at the various study sites. As a significant contributor to moderate to
severe diarrhea, Cryptosporidium was also associated with a higher incidence of linear
growth faltering (Nasrin et al. 2021). Malnutrition and Enteric Diseases (MAL-ED) was a
birth cohort study across eight study sites that followed children up to 2 years of age
(Platts-Mills et al. 2018). Again, Cryptosporidium was identified as a major contributor to
diarrheal disease in the first 2 years of life with it being the fifth and seventh most common
infection in 0-11 months and 12-23 months, respectively. MAL-ED also confirmed the
association between growth faltering and Cryptosporidium infection (Korpe et al. 2018).

1.3.2 Diagnostics
Diagnosing infections caused by Cryptosporidium has long relied on fecal
floatation and analysis by microscopy to detect oocysts. The moderate sensitivity of this
method led to the underdiagnosis of cases with numerous studies showing that cases
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identified as negative by microscopy tested positive by PCR. Immunoassays that detect
parasite antigen have become commercially available and are increasingly used in
laboratory settings due to the high throughput nature of these tests. There is significant
variability amongst these assays and their ability to detect species other than C. hominis
and C. parvum is generally low (Chalmers et al. 2011). PCR is being used more frequently
for screening a range of intestinal infections. PCR also allows for genotyping at the gp60
locus to discriminate between species, sequencing the gp60 locus also allows for
subtyping within species. PCR is highly sensitive, but it requires expensive instrumentation
and technical skill making its use in the field cumbersome. Rapid molecular tests that
reduce the requirement for specialized skills and equipment are under development (Yu
et al. 2021).
Serological assays have been employed for epidemiological studies. IgA can be
used to indicate current or recent infections while IgG responses indicate past infections.
Antibodies to different surface antigens of the parasite have been shown to correlate with
different disease histories. Antibodies to Cp23 correlate with distant infection while gp15
responses reflect more recent exposure, and responses to P2 have been associated with
repeat infections (Priest et al. 2006). Luminex-based assays have been developed to
detect Cryptosporidium along with numerous other neglected tropical diseases in blood
and saliva assays (Griffin et al. 2011, Lammie et al. 2012).
Detection of Cryptosporidium in source water is also a valuable diagnostic tool.
Cryptosporidium causes both waterborne and foodborne outbreaks, C. hominis is more
associated with waterborne transmission with C. parvum more associated with foodborne
transmission (Zahedi and Ryan 2020). Cryptosporidium is also the fifth most important
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cause of foodborne illness worldwide (Ryan et al. 2018). The World Health Organization
categorizes Cryptosporidium as a reference pathogen for the quality of drinking water
(Medema et al. 2006). Microscopy, immunoassay, and PCR can all be utilized with water
samples following concentration by centrifugation.

1.3.3 Therapeutics
Treatment for cryptosporidiosis is still underdeveloped. Nitazoxanide (NTZ) is the
only FDA-approved drug for the treatment of Cryptosporidium infection in the United
States, unfortunately, it is not efficacious in immunocompromised people (Amadi et al.
2009). In addition, the efficacy of NTZ treatment ranges from 56-96% in immunocompetent
hosts (Rossignol et al. 2001, Rossignol et al. 2006). NTZ, a thiazolide, is known to act as
a pyruvate: ferredoxin oxidoreductase inhibitor and its effect on the host cell has allowed
it to be used broadly for the treatment of many intracellular infections (Hoffman et al. 2007,
Rossignol 2014). Paromomycin is another drug with demonstrated anti-cryptosporidial
action (Marshall and Flanigan 1992) but this drug is also ineffective at treating disease in
HIV positive patients (Hewitt et al. 2000). The most successful forms of treatment for
immunocompromised individuals are treatments that boost immune function. The use of
antiretroviral therapy in patients with HIV was protective against Cryptosporidium infection
(Manabe et al. 1998).
Clofazimine is one of the recent promising drug candidates for use against
Cryptosporidium. Clofazimine is a repurposed approved drug for leprosy that was shown
to reduce oocyst shedding using three daily doses or a single high dose in mouse models
(Love et al. 2017). Unfortunately, a Phase 2 clinical trial did not demonstrate the efficacy
of clofazimine for treatment for cryptosporidiosis in patients with HIV (Iroh Tam et al. 2020).
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The study was confounded by low enrollment and a failure of randomization (Huston
2020). New drug candidates continue to be developed including drugs that target PI4K
(Manjunatha et al. 2017), tRNA synthetases (Baragaña et al. 2019, Vinayak et al. 2020),
calcium-dependent kinases (Hulverson et al. 2021), and numerous compounds with
currently unknown modes of action (Jumani et al. 2018, Lunde et al. 2019). Ideal drugs
for the treatment of cryptosporidiosis would be those with high bioavailability in the gut,
single dose, or courses lasting less than 7 days. One of the major challenges is the
confounding factor of co-infections which are prevalent in regions with high burdens of
Cryptosporidium (Taniuchi et al. 2013).
Improvement of water quality is an important strategy for reducing the risk of
diarrheal diseases altogether. While studies have shown that environmental interventions
such as improved water supply and hand hygiene education are effective, individual
household measures show the greatest effectiveness (Clasen et al. 2007). Evidence from
the GEMS study also indicates that increasing access to household sanitation facilities
would reduce the risk of moderate to severe diarrhea (Baker et al. 2016).

1.3.4 Environmental Enteropathy
Cryptosporidium has often been denoted as a disease of poverty with low- and
middle-income countries being most greatly affected by the long-lasting effects of this
infection. While Cryptosporidium can lead to severe disease and death, even those
children that experience asymptomatic infections are more likely to become malnourished,
stunted, and experience delayed cognitive development. This vicious cycle between,
infection, malnutrition, growth impairment, and cognitive delay are the hallmarks of the
state of “environmental enteropathy”. As one of the most common infections in children
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under the age of two, Cryptosporidium is linked with many of the other factors implicated
in environmental enteropathy.
Malnutrition predisposes children to cryptosporidiosis and infection, in turn,
worsens intestinal function further reducing the uptake of nutrients (Coutinho et al. 2008,
Mondal et al. 2011). Weight loss commonly occurs during diarrheal episodes leading to
the conclusion that weight loss from diarrhea is to blame for ensuing malnutrition. Even
asymptomatic infections with Cryptosporidium led to a decreased ability to gain weight
following infection in a cohort of children under the age of 3 (Checkley et al. 1997). These
data point to possible metabolic and microbiome changes that occur even in the absence
of diarrhea. Evidence for changes in the microbiome during Cryptosporidium infection has
been found in mouse models of infection (Ras et al. 2015). Metabolites associated with
immature microbiomes promote the growth of C. parvum (VanDussen et al. 2020).
Malnutrition predisposes children to dysbiosis and evidence of a causal relationship
between an altered microbiome and severe malnutrition has been found (Kane et al.
2015). In some cases of severe acute malnutrition, therapeutic food intervention failed to
correct stunting and this was associated with a persistently immature microbiome
(Subramanian et al. 2014).
Studies into an intervention to reduce deaths of children due to diarrheal diseases
suggest zinc supplementation is necessary for optimal recovery from malnourishment
(Arifeen et al. 2009). An amino acid based elemental diet also promoted recovery from the
cycle of diarrhea and malnutrition (Amadi et al. 2005). Better models to study the
phenomenon of environmental enteropathy that recapitulate the key findings of cognitive
impairment and altered metabolism are sorely needed.
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Although discussed in the context of Cryptosporidium infection, environmental
enteropathy is associated with several infections, especially co-infections, as enteric
infections are common in areas with a high burden of stunting.

1.4 Interferon Lambda, defender of mucosal barriers
Interferons were first discovered in 1957 and named for their ability to interfere with
viral replication (Isaacs and Lindenmann 1957). We now know that interferons play a role
in host defense against numerous intracellular pathogens. There are three families of
interferon cytokines. There are 17 type I interferons, with IFNα and IFNβ being the most
prominent. Type II interferon is represented by a single cytokine, interferon gamma, which
is known for its potent effects against a range of intracellular pathogens. The most recently
discovered class are type III interferons, or interferon lambda (IFNλ). In humans there are
IFNλ1-3, sometimes denoted as IL29 and IL28A and IL28B. In mice, Ifnl1 is a pseudogene,
and therefore mice encode only Ifnλ2 and Ifnλ3.

1.4.1 Induction
Type III interferon production is initiated in response to many of the same signals
typical of viral infection that stimulate the production of type I interferon, namely ssRNA,
dsRNA, and cytosolic DNA (Figure 1.4). The following pattern recognition receptors have
been shown to lead to production of IFNλ in certain cell types: RIGI-like receptors (RLRs),
TLR3, TLR9, and Ku70. To date, only activation of Ku70, the cytosolic DNA sensor, has
been shown to uniquely initiate transcription of IFNλ but not IFNα/β (Zhang et al. 2011,
Sui et al. 2017). The localization of components of the recognition machinery plays a role
in differentiating between induction of IFNλ vs IFNα/β. MAVS localized to peroxisomes, as
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opposed to the mitochondria, preferentially induced IFNλ and this was correlated with the
abundance of peroxisomes which increases with the polarization of epithelial cells
(Odendall et al. 2014). IFNλ induction depends more strongly on MAPK and NF-κB
signaling than does IFNα/β signaling (Iversen et al. 2010, Pervolaraki et al. 2017).
Different members of the interferon regulatory factor (IRF) family are required to
varying extents depending on the interferon promoter region. IRF3 was shown to induce
production of IFNλ1 but only weakly induced IFNλ2/3 (Österlund et al. 2007). The
importance of IRF1 for induction of IFNλ may be context dependent. Induction of
inflammatory genes, including CXCR3 chemokines, was shown to require upregulation of
IRF1 which only occurred in response to type I IFNs and not type III IFNs (Forero et al.
2019). Type III IFN inhibits replication of enterovirus 71 via a TLR3-IRF1 axis
demonstrating IRF1 still plays a role in IFNλ induction (Good et al. 2019).
Med23, a component of the Mediator complex which is utilized by viruses like HSV1 to promote their replication, was found to be a potent inhibitor of HSV-1 replication
(Griffiths et al. 2013). The mechanism of Med23 was through interaction with IRF7 and
binding to the IFNL1 promoter, this did not occur for induction of type I interferons. Using
chromatin immunoprecipitation (ChIP) and reporters for the IFNL1 promoter the
transcriptional repressors ZEB1 and BLIMP1 were identified in airway epithelial cells
(Siegel et al. 2011). The importance of ZEB1 and BLIMP-1 as repressors of type III
interferon transcription was confirmed in human colon epithelial cells (Swider et al. 2014).
ZEB1 is specifically a regulator of type III interferons while BLIMP-1 displaces IRF1
allowing it to modulate both type I and type III interferon expression.

41

Figure 1.4 Induction of type III IFNs
Pattern recognition receptors of the cytoplasm and the endosome recognize nucleic acids to induce
expression of type I and III IFNs

1.4.2 Signaling
The downstream transcriptional response to type I and type III interferons is
remarkably similar, though type I IFNs bind IFNAR (a heterodimer of IFNAR1 and IFNAR2)
while type III interferons bind a heterodimer of IFNLR1 and IL10RB. IFNAR is ubiquitously
expressed while IFNLR1 is limited to cells primarily at mucosal sites, mainly epithelial cells
(Sommereyns et al. 2008). The structure of IFNλ resembles an IL-10 family member but
sequence similarity supports its designation as an interferon (Gad et al. 2009, Miknis et
al. 2010). Engineering of an IFNλ3 with enhanced binding affinity for the IL10RB subunit
enhanced the antiviral and antiproliferative effects but the same effect is not observed with
high-affinity type I IFN (Mendoza et al. 2017). When an interferon binds to its receptor the
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Janus kinase (JAK)-signal transducer of transcription (STAT) signaling cascade is
initiated. JAK1 phosphorylates STAT1 and TYK2 phosphorylates STAT2, IRF9 binds to
form a heterotrimer known as interferon stimulated gene factor 3 (ISGF3). ISGF3
translocates to the nucleus and induces the expression of hundreds of ISGs. The
transcriptional responses largely overlap and no signatures entirely unique to IFNλ have
been identified. In contrast to type I and II IFN, treatment with type I or type III IFNs induce
expression of type III IFNs making them ISGs as well (Ank et al. 2006). The transcriptional
response to IFNλ has been shown to be peak later than type I and to last longer.
Evaluation of a patient with TYK2 deficiency showed no defect in the type III interferon
response but a complete abrogation of the type I interferon response suggesting TYK2
may be dispensable for the action of IFNλ (Fuchs et al. 2016). Interferons also induce
negative regulators of the response. USP18 was shown to specifically desensitize cells to
IFNα but not to IFNλ (François-Newton et al. 2011). SOCS1 regulates both type I and
type III IFN signaling but SOCS3 had no role in type III IFN (Blumer et al. 2017). Zinc is
an inhibitor of IFNλ by disrupting binding to its receptor (Read et al. 2017).
While response to type III IFN is primarily found in epithelial subsets some immune
cells also respond. Human monocytes and macrophages produce IL-6, IL-8, and IL-10 in
response to IFNλ (Jordan et al. 2007). Human B cells produce IL-6 and IgG and IgM in
response to IFNλ which is enhanced in the presence of agonists of TLR7 and TLR9 (de
Groen et al. 2015). Greater characterization of the additional cells that may respond to
IFNλ is needed.
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1.4.3 Viral infections
IFNλ has been shown to restrict the replication of many viruses; SARS-CoV1,
SARS-CoV2, respiratory syncytial virus (RSV), influenza, human metapneumovirus, HIV,
and many others have all been shown to be inhibited by IFNλ (Ye et al. 2019, Felgenhauer
et al. 2020). Type III IFN promotes an antiviral state that is similar to type I IFN but with
some notable differences.
Respiratory Viruses
IFNλ is the predominant IFN produced in response to influenza (Jewell et al. 2010).
It is also the first IFN produced, detectable within 24 hours of infection, while type I IFN
can only be detected 3 days post-infection unless high doses of influenza (> 5000 pfu) are
given (Galani et al. 2017). At sublethal doses (10 pfu) IFNλ is essential for early antiviral
control while type I IFN are dispensable. The epithelial cells and neutrophils are the major
targets of IFNλ in the lung. IFNλ and type I IFN induced similar antiviral gene expression
signatures, but a notable absence of pro-inflammatory factors was observed in response
to IFNλ. The importance of IFNλ for early control of influenza was extended to demonstrate
that IFNλ was specifically required to prevent dissemination from the upper airway to the
lungs (Klinkhammer et al. 2018). Mice lacking IFNLR1 also had higher rates of
transmission of influenza or SeV between cage mates. Part of this mechanism depends
on baseline IFNλ production in the upper airway which requires intact type I IFN signaling.
Intranasal treatment of mice with IFNλ inhibited viral replication in the upper airway while
no such effect was observed with IFNα treatment. This phenomenon may be explained by
the transient nature of the response of airway epithelial cells to IFNα.
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Type III IFN can also modulate adaptive immune responses as has been
demonstrated during influenza infection. Secretion of IFNλ by airway epithelial cells
following influenza infection-induced production of cytokine thymic stromal lymphopoietin
(TSLP) by M cells (Ye et al. 2019). TSLP acts on CD103+ DC and helps to induce IgG1
and IgA and antigen-specific T cells following infection or vaccination. The migration and
function of CD103+ DC were dependent on IFNλ signaling to induce optimal CD8 T cell
responses to influenza (Hemann et al. 2019).
Although IFN responses are critical to viral control, production of IFNλ can also
have detrimental consequences. High expression of both type I and type III IFN in the lung
of patients with COVID-19 was correlated with morbidity (Broggi et al. 2020). IFNλ also
restricted the growth of airway epithelial cells in a p53 dependent manner disrupting repair
of the lung epithelial barrier following influenza infection (Major et al. 2020). In one study,
IFNλ was shown to be produced by pDC indicating that the source of IFN may also have
an effect on the outcome of the IFN signaling induced (Broggi et al. 2020). Together, these
studies demonstrate the importance of timing and duration of IFN responses for balancing
viral clearance with barrier repair and recovery.
Enteric Viruses
In the gut the interferon response is compartmentalized, with IECs producing and
responding to type III IFN and immune cells the producers and targets of type I IFN
(Mahlakõiv et al. 2015). This response is also age dependent with IECs in adult mice
having a reduced ability to respond to type I IFN. With type I and III IFN sharing many
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functions, it has been posited that type III IFN evolved to promote less inflammatory
responses that are restricted to mucosal barriers.
IFNλ but not IFNα/β were able to cure persistent enteric infections with murine
norovirus (Nice et al. 2015). Type I IFN was required to control systemic norovirus in line
with the compartmentalization of IFN response in the gut. As a virus with broad host cell
tropism, reovirus studies demonstrated the separate roles of type I and III IFN in control
of viral infections. It was demonstrated that type III IFN signaling specifically prevents
replication of the virus in IECs, whereas type I IFN signaling limits replication in lamina
propria cells and systemic spread of the virus (Mahlakõiv et al. 2015). Antibiotic
pretreatment of mice prevented the establishment of intestinal infection with norovirus
(Baldridge et al. 2015). This effect required intact IFNλ signaling suggesting an impact of
the microbiome on the ability of IFNλ to limit viral replication in the gut.
Rotavirus is the leading cause of diarrheal disease in children under the age of 5.
Rotavirus strictly infects epithelial cells. Type III IFN is protective in homologous infection
models i.e. murine rotavirus in mouse models (Pott et al. 2011). Different observations
have been reported with respect to the contribution of IFN to control infections with
heterologous rotavirus challenge, but the consensus is that both type I and III IFN are
required (Feng et al. 2008). In heterologous challenges with simian rotavirus, both type I
and type III IFN cooperated to limit the spread of the virus (Lin et al. 2016). IL-22 acted
synergistically with IFNλ to control rotavirus infection (Hernández et al. 2015). IL-1α was
produced by IECs in response to rotavirus which signals to ILC3 cells to make IL-22. The
authors showed synergy between IL-22 and IFNλ with poliovirus and VSV as well. In a
mouse model of dextran sulfate sodium (DSS) colitis, enteric viruses were shown to
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protect the host from colitis due to the action of IFNλ on neutrophils, which reduced the
production of reactive oxygen species and degranulation via a transcription-independent
mechanism (Broggi et al. 2017).
Hepatotropic Viruses
The role of type III IFN in control of viral infections of the liver has been largely
evaluated in human studies as mouse hepatocytes do not respond to IFNλ, only the
cholangiocytes of the bile duct upregulate ISG expression in response to type III IFN in
mice (Hermant et al. 2014). Consistently, IFNλ was not found to be important to immunity
against hepatotropic viruses in mice (Mordstein et al. 2008). Studies of hepatitis C
infection revealed a new type III IFN, IFNL4, which is only transcribed in individuals
carrying a ΔG variant at ss469415590 (Prokunina-Olsson et al. 2013). The ΔG variant is
associated with impaired clearance of hepatitis C virus. One mechanism considered here
is the ability of IFNλ4 to more potently induce negative regulators of type III IFN signaling
(Obajemu et al. 2017). The ΔG variant is also associated with increased ISG expression
in the PBMCs of patients with chronic hepatitis C infection in the absence of treatment
(Rosenberg et al. 2018). Recent work indicates there is also an association between the
ΔG variant and impaired clearance of upper respiratory infections (Rugwizangoga et al.
2019).

1.4.4 Bacterial Infections
Similar to type I interferons, induction of type III interferons during bacterial
infections are not always beneficial to the host. IFNλ has been shown to be induced in
colon epithelial cells lines in response to Gram-positive bacteria, including Listeria
47

monocytogenes, Staphylococcus aureus, Staphylococcus epidermis, and Enterococcus
faecalis, but not Gram-negative bacteria including Salmonella enterica Typhimurium,
Shigella flexneri, and Chlamydia trachomatis (Bierne et al. 2012). Concentrations of IFNλ2
were elevated in the sputum of patients with pulmonary tuberculosis (Travar et al. 2014).
Type III interferons may still be induced in vivo in response to damage caused by infection.
Listeria infection is reduced in the absence of IFNλ induction and it encodes an effector
protein, LntA, that induces type III interferons by targeting BADH1 a STAT1 repressor
(Lebreton et al. 2011). The role of type I interferons in Listeria infection depends strongly
on the method of infection, with oral infection being the natural route. Oral infection models
are limited as mice are not a natural host, but these models typically show a protective
role for type I interferons preventing the dissemination to other organs. Infections of the
lung with MRSA and P. aeruginosa were exacerbated in mice with intact IFNλ signaling,
this was likely due to the IFNλ dependent increase in pro-inflammatory cytokines such as
TNFα and IL-1β (Cohen and Prince 2013).
Salmonella infection induced secretion of IFNλ in human monocyte-derived DC but
this did not require new protein synthesis (Pietilä et al. 2010) but was dependent on
phagocytosis as well as intact p38 MAPK, PI3K, and NF-κB signaling. Treatment of
polarized epithelial cells with IFNλ1 abrogated the loss of transepithelial electrical
resistance (TEER) following infection with Salmonella (Odendall et al. 2017).

1.4.5 Fungal Infections
The role of IFNλ during fungal infections has only recently been explored. The most
prominent role for type III interferons during fungal infection reported thus far was its
effects on neutrophil function in mice. Neutrophil-specific deletion of the IFNLR1 or STAT1
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prevented mice from containing Aspergillus fumigatus infection (Espinosa et al. 2017).
This result was due to the act of IFNλ as a potent inducer of reactive oxygen species in
neutrophils. The C-type lectin, Dectin1 was shown to recognize βglucan on the surface of
A. fumigatus leading to type I and type III interferon production (Dutta et al. 2020). Candida
albicans is also recognized by Dectin1 suggesting it has the potential to stimulate IFNλ
production as well (del Fresno et al. 2013). Further studies of immunity to fungal infections
of the respiratory tract may reveal additional roles for IFNλ against these pathogens.

1.4.6 Parasitic Infections
The role of type III interferons in parasitic infections is understudied. The first such
study examined the systemic profile of type III interferons in humans infected with
Strongyloides stercoralis before and after anthelminthic treatment (Rajamanickam et al.
2018). Elevated levels of type III interferons in the serum correlated with elevated numbers
of plasmacytoid DCs in the circulation. Type III interferons and numbers of DCs decreased
following treatment. While this study did not demonstrate a protective or deleterious effect
of IFNλ during helminth infection, it suggested the need to examine the role of type III
interferon further.
An association was found between the incidence of clinical malaria and the ΔG
mutation leading to the expression of IFNL4 (Samayoa-Reyes et al. 2021). Children in
Kenya carrying the ΔG mutation also had an earlier time to first malaria infection during
the first two years of life. Type I IFNs are upregulated in response to Plasmodium infection
of hepatocytes in mice (Liehl et al. 2014) but further work is necessary to evaluate the role
of IFNλ in malaria.
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IFNλ is protective during C. parvum infection (Ferguson et al. 2019). IFNλ was
highly upregulated upon infection using both neonatal piglet and neonatal mouse models
of infection. Antibody blockade of IFNλ2/3 increased parasite numbers, and to a lesser
extent pathology, in neonatal mice. In vitro studies using a primary porcine jejunal cell line
showed that C. parvum infection induced a loss of transepithelial resistance (TEER) and
this loss was abrogated upon treatment with IFNλ. The authors suggested the mechanism
of action of IFNλ to be inhibition of parasite invasion. This study represents the first
evidence of IFNλ being important for immunity against a protozoan parasite.
Type III IFN acts primarily at mucosal sites with extensive characterization of its
antiviral activity in epithelial cells. Recent work has demonstrated non-redundant roles for
type III IFN that cannot be compensated for by type I IFN. The increasing work on IFNλ
has revealed pronounced effects on neutrophil function that may extend the importance
of this antiviral cytokine further into other infections. Future work on the impact of IFNλ
signaling on adaptive immunity is also warranted.

1.4 Dissertation Aims
Cryptosporidium is the second leading cause of diarrheal disease in infants
worldwide, but no effective treatment has been found to control this highly prevalent
human pathogen. Studies of the immune response to infection have focused largely on
IFNγ and T cells, undoubtedly critical mediators of protection, but additional mechanisms
shape the host response to Cryptosporidium in important ways. The central role of the
epithelial cell in the response to Cryptosporidium that is emerging is not yet widely
acknowledged. A deeper understanding of how the host recognizes and seeks to limit the
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infection, and how, in turn, the parasite manipulates the host to ensure its survival will
allow us to develop new tools to study and control this clinically important parasite.
Therefore, the aims of this dissertation are as follows:

1.4.1 Identify host factors that are critical to Cryptosporidium infection.
The development of screening platforms using CRISPR-Cas9 has improved our
understanding of host-pathogen interactions in bacterial, viral, and parasitic infections. In
CHAPTER 3, we use a genome-wide CRISPR-Cas9 knockout screen to identify host
genes required for susceptibility to Cryptosporidium and parasite-induced cell death. We
identified 35 genes and three pathways that were important for susceptibility. Our work
supported the finding of a C-type lectin on the surface of the parasite that binds to host
glycosaminoglycans. We also identify a host factor, CD151, that is implicated in the
invasion of HSV-1 and localizes to the invasion site during Cryptosporidium infection. The
remaining candidates provide a curated list of host factors to evaluate in future studies.

1.4.2 Evaluate the role of type III interferon signaling during Cryptosporidium
infection.
Our screen in CHAPTER 3 documented the importance of IFN signaling during
Cryptosporidium infection. In CHAPTER 4, we investigate the origin of this response and
characterize the type of IFN signaling induced. We demonstrate the preferential induction
of type III interferons upon infection of human host cells. Live infection is shown to be
required with the response being initiated in infected cells. Mice lacking the type III
interferon receptor showed an early increase in susceptibility to infection. Treatment with
IFNλ protected mice from infection in the absence of IFNγ and adaptive immunity. We
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conclude that type III interferons are important for innate immune defense against
Cryptosporidium infection.

1.4.3 Identify the pattern recognition receptor that recognizes Cryptosporidium and
induces IFNλ production.
Only one pattern recognition receptor thus far has been shown to recognize
Cryptosporidium, NLRP6 (Sateriale et al. 2021). There is a body of literature on the
importance of TLR4 during Cryptosporidium infection, but our work in CHAPTER 4
demonstrated that heat-killed parasites did not induce IFNλ suggesting the PRR is likely
intracellular. In CHAPTER 4, we screened a library of agonists of PRR for their ability to
induce type III interferon production in HCT-8 cells. Only agonists against TLR3, TLR7,
and the RLRs, MDA5 and RIG-I were shown to induce IFNλ production in our cell line.
Mice lacking MAVS and TLR7 showed no difference in susceptibility to infection. Tlr3-/mice were more susceptible to infection and induced no detectable IFNλ in response to
C. parvum infection. Our data indicate that TLR3 recognizes Cryptosporidium and induces
type III interferons.
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CHAPTER 2: MATERIALS AND METHODS
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Ethics Statement
All in vivo experiments were performed in accordance with protocols for animal care
approved by the Institutional Animal Care and Use Committee at the University of
Pennsylvania (#806292).

Mice
C57/BL6J (stock no: 000664), B6129 (stock no: 101045), Ifng-/- (stock no: 002287),
Ifnar-/- (stock no: 028288), Vil1 Cre (stock no: 021504), Mavs -/- (stock no: 008634), Tlr3 -/(stock no: 005217), Tlr7-/- (stock no: 008380) mice were purchased from Jackson
Laboratories. C57/BL6 (Model no: B6NTac), Rag2 -/- (Model no: RAGN12), Rag2 -/- Il2rg-/(Model no: 4111) mice were purchased from Taconic Biosciences. Vil1-Cre (stock
no:021504) were purchased and STAT1flox mice were generated as previously described
(Klover et al. 2010) and maintained in house. Il28ra -/- mice (Ank et al. 2008) (Bristol Meyers
Squibb) were maintained in house. Mice used in this study were males or females between
6-10 weeks of age. All mice were sex and age matched for each experiment. No
differences in infection were observed between male and female mice.

Cells, Parasites, and Infections
HCT-8 cells (ATCC) were maintained in RPMI supplemented with 10% FBS at 37°C and
5% CO2. Wild-type Cryptosporidium parvum oocysts used in this study were purchased
from Bunchgrass Farms (Dreary, ID). Parasites expressing Tandem mNeon were
generated in a previous study (Dumaine et al. 2021). For in vitro infections oocysts were
incubated in a (1:3) bleach: water solution for 10 minutes at 4°C, centrifuged then
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resuspended in a 0.08% solution of sodium deoxytaurocholate and incubated at 16°C for
10 minutes. Oocysts were then washed in PBS and finally resuspended in infection media
(complete RPMI with 1% FBS) and added directly to host cells.
C. parvum oocysts used for all in vivo experiments are mouse adapted mCherry and
Nanoluciferase expressing (Sateriale et al. 2021). Mice were infected with 50,000 C.
parvum oocysts by oral gavage unless otherwise noted.

Killing Assay
6 well cultures grown to 60% confluency were infected with 5 x 105, 1.25 x 106, 2.5 x 106,
3.75 x 106, or 5 x 106 oocysts per well in biological duplicate. Following a 72-hour infection,
cells were trypsinized and incubated in a 1:4 solution of Trypan Blue. Cells were counted
and Trypan Blue exclusion used to determine viability.

CRISPR Screen
The Brunello CRISPR sgRNA library (Doench et al. 2016) was optimized for on-target
activity and to minimize off-target effects. Brunello contains four sgRNAs per protein
coding gene in the human genome. HCT-8 in media containing 1μg/mL polybrene were
spinfected (2 hours, 30°C at 1,000xg) with lentivirus to produce a constitutively expressing
Cas9 cell line (lentiCas9-Blast, plasmid#52962, addgene). Following a 7-day selection
with blasticidin (1.5μg/mL), cells were diluted to generate clonal Cas9 expressing cell
lines. To measure Cas9 activity these cells were subjected to an EGFP reporter assay for
Cas9 activity. Cas9 expressing cells were spinfected with lentiXPR_011, encoding an
EGFP and a sgRNA targeting EGFP. 24 hours post spinfection cells were flow sorted to
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assess green fluorescence. Cells lacking or stably expressing EGFP expressing were
used as controls for flow cytometry.
We sought to achieve 1000-fold coverage across multiple biological replicates of the
screen. Each replicate achieved 500-fold coverage. Per mL of the Brunello library there
were 4.2 x 107 lentiviruses/guides. We infected at an MOI of 0.4 therefore 1.02 x 10 8 cells
were transduced with the library. These cells were trypsinized and spinfected as before
into a total of six 6-well plates. Plates were incubated at 37°C, 5% CO2 for 24 hours then
media was changed to include 1ug/mL puromycin for selection of transduced cells. Seven
days later, cells were trypsinized and expanded into 12 T-175 flasks. After expansion,
genomic DNA was isolated from four flasks as the input population and at least 4 x 10 7
cells (500-fold coverage) were passaged into 4 T-175. These 4 T-175 were then infected
with a 90% kill dose of C. parvum oocysts. After 72 hours media was replaced with fresh
media and cells were allowed to recover. Once confluent, cells were trypsinized and
seeded into new flasks to be re-infected while at least 4 x 10 7 cells were taken for genomic
DNA extraction. In total, the population was subjected to three rounds of successive C.
parvum infection.
Genomic DNA was extracted using the QIAamp DNA Blood Maxi kit (Qiagen). sgRNAs
were amplified by PCR as described (Doench et al. 2016). Read counts were normalized
to reads per million in each condition.

MAGeCK Analysis of CRISPR Screen
Data from our CRISPR screen was analyzed using MAGeCKFlute in R (Wang et al. 2019).
MAGeCK uses a negative binomial to test for differences in sgRNA abundance between
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conditions (Li et al. 2014). The input population for Clone K was compared to the output
of each round of infection. For Clones C and I input was compared only to the final
population. Results shown are for the combined data of screens with Clone I and K. Clone
C was excluded due to poor sequencing depth. Genes with three or four sgRNAs positively
ranked by the robust ranking aggregation (RRA) algorithm and an FDR of less than 0.05
were considered significantly enriched. Pathways identified by GSEA that included
multiple genes of the top candidates were displayed in Fig 1.

RNAi Screen
siRNAs targeting top screening candidates were purchased from Ambion (ThermoFisher
Scientific, Waltham, MA). Both scrambled non-targeting siRNAs and a positive
transfection control RNA targeting GAPDH were included. siRNAs were delivered to 96
wells at 50% confluency using Lipofectamine RNAiMax (ThermoFisher Scientific,
Waltham, MA) to a final concentration of 100nM per well. 24 hours later, wells were
infected with 25,000 C. parvum oocysts. At 48 hours post infection, cells were lysed and
RNA extracted using the Rneasy Mini Kit (Qiagen). Knockdown of target genes was
assessed by qPCR. Host cell viability was measured by MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) assay. Briefly, media was removed from all wells and
replaced with 100μL of fresh RPMI. 10μL of 12mM MTT solution was added to each well.
Plates were incubated at 37°C for 4 hours. Then all media was removed and replaced with
50μL of DMSO (Sigma, St. Louis, MO) and mixed thoroughly by pipetting up and down.
Following a 10 minute incubation at 37°C, plates were read for absorbance at 540nm.
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Lentivirus preparation
HEK293T cells were transfected using the Lipofectamine 3000 (ThermoFisher) protocol
to produce lentiviral particles. 6μg of VSVg, 8μg PAX2, 11μg transfer vector (varied based
on experiment) were combined. 50μL of P3000 reagent was added followed by 500μL of
OptiMEM. Then 500μL of OptiMEM combined with 25μL of Lipofectamine reagent is
added with the whole solution incubated at room temperature for 20 minutes. A T-75 flask
of HEK293T cells at approximately 80% confluency were trypsinized and ½ of each flask
was used per lentivirus preparation. The lipofectamine solution was combined with the
HEK293T cells into a new flask in OptiMEM for 6 hours at 37°C. After the 6 hour
incubation, media was changed to DMEM + 1% BSA and incubated for 60 hours at 37°C.
Supernatant was collected, centrifuged at 2500 rpm for 5 minutes at 4°C, and filtered
through a 0.45 μm filter. Lentiviral was concentrated with centrifugation at 15,000 xg for
15.5 hours at 4°C. Supernatant was removed and the pellet resuspended in 1-2mL of
DMEM + 1% BSA. Lentivirus was stored at -80°C. To generate stable cell lines 24 well
cultures of HCT-8 at 50% confluency were spinfected (1,000xg for 2 hours at 30°C) in the
presence of 1μg/mL polybrene and 100μL of lentivirus. After an overnight incubation in
fresh media, antibiotic was added to select for cells positive for transfection. All stable cell
lines were cloned out by limiting dilution in 96 well plates.

Single gene knockout HCT-8 cells
Primers used to generate sgRNA for each gene targeted can be found in Table 1, sgRNA
sequences were derived from the Brunello library (Doench et al. 2016). All sgRNA oligo
sequences were cloned into the pLentiGuide-Puro plasmid (plasmid #52963, addgene)
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according to protocols (Sanjana et al. 2014). Briefly, 5µg of plasmid pLentiGuide-Puro was
digested with Esp3I (ThermoFisher, FD0454) and purified using the Accuprep PCR/Gel
extraction kit (Bioneer, K3037). Pairs of oligos were annealed and phosphorylated with T4
PNK (NEB, M0201S) in T4 DNA ligase buffer in a thermocycler with the following
parameters: incubation for 30 minutes at 37°C, then incubation at 95°C for 5 min with a
ramp down 5°C per minute until to 25°C. Oligos were then diluted 1:200 and 1µl of the
diluted oligo mixture was ligated with 50ng of Esp3I digested plasmid. Ligation reactions
were transformed into NEB Stable Competent E. coli (NEB, C3040H) and transformed
clones were checked by colony PCR and DNA sequencing. Lentiviral transduction of
sgRNAs cloned into pLentiGuide-Puro into Cas9 Clone K HCT-8 cells was performed as
described above, and after 7 days of selection with 1µg/ml puromycin the populations
were cloned out by limiting dilution. Genomic DNA was extracted from each clone and the
region surrounding the sgRNA was amplified by PCR and cloned into the pCR 2.1 TOPO
TA vector (ThermoFisher, 450641). At least four colonies were sent for DNA sequencing
for each clonal KO cell line. Sequences were mapped and assessed for insertions and
deletions.

Complementation of HCT-8 knockout cell lines
cDNA clones of genes to be complemented were cloned into a lentiviral expression vector,
pLX304 (plasmid #25890, addgene) to achieve stable expression. A Gateway cloning
strategy was employed and was carried out according to the protocol supplied with the
Gateway Technology with Clonase II kit (ThermoFisher, 12535029). Briefly, cDNA from
HCT-8 cells was used to PCR amplify genes of interest with attB overhangs. PCR products
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were combined with pDONR211 vector for the BP reaction producing an expression vector
with the gene of interest. The donor vector was then combined with pLX304 in the LR
reaction producing the lentiviral vector with the gene of interest under a CMV promoter
and a C-terminal V5 tag. Lentivirus was prepared as detailed above.

Invasion assay
96 well cultures of HCT-8 at 50% confluency, cells were incubated in IFNλ for 16 hours
prior to infection. Cp Neon oocysts were excysted as above with an additional 1-hour
incubation at 37°C following the sodium deoxytaurochloate step. After a final wash,
parasites were added directly to 96 well plates of HCT-8 cells and allowed to invade for 2
hours at 37°C. Cells were then fixed in 4% paraformaldehyde in Hanks Balanced Salt
Solution (HBSS). Primary antibody was diluted in a 3% BSA solution in HBSS. 1:100 anti
Cp-23 (LS-C137378-100, LS Bio, Seattle, WA) was incubated at room temperature for 1
hour. Secondary antibody goat-anti mouse 594 (ThermoFisher) was diluted 1:1000 in 3%
BSA solution in HBSS and incubated at room temperature for 30 minutes. Cells were
incubated for 5 minutes in a 1:3,000 Hoechst solution. Finally, a PBS wash was performed
and wells were filled with 100μL of PBS for imaging. Microscopy was done using the Image
Xpress Micro High Content Imaging Device. 16 images were taken per well with Z-slices
of 17μm. 2D Z-projections were then quantified for green, labeling all parasites, or green
and red, labeling non-invaded sporozoites. Percent invasion was calculated for each well.
Immunofluorescence assay
Infected HCT-8 coverslip cultures were fixed in 4% paraformaldehyde and permeabilized
with 0.1% Triton X-100 for 10 minutes each at room temperature. Samples were blocked
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in 3% Bovine Serum Albumin (BSA) for 1 hour and primary antibodies were diluted in 3%
BSA. Anti-CD151 (ab33315, Abcam) was diluted 1:100 and anti-Tryptophan synthase
beta (Vinayak et al. 2015) was diluted 1:1000. Secondary antibodies (ThermoFisher) were
diluted 1:1000 in 3% BSA. FITC conjugated phalloidin (F432, ThermoFisher) was included
in the secondary antibody incubation. Cell nuclei were labeled with Hoechst 1:10,000 for
5 minutes and coverslips were mounted using Vectashield (Vector Laboratories). Slides
were imaged using a Leica DM6000 Widefield microscope.

RNA sequencing
Total RNA was extracted using the RNeasy Mini (48-hour) RNeasy Micro (10-hour) kit
(Qiagen). cDNA was synthesized using the SMART-Seq v4 Ultra Low Input RNA Kit
(Takara Bio USA), and barcoded libraries were prepared using the Nextera XT DNA
Library Preparation Kit (Illumina). Total RNA and libraries were quality checked and
quantified on an Agilent Tapestation 4200 (Agilent Technologies). Samples were pooled,
and single-end reads were run on a NextSeq 500 (Illumina).
Reads were pseudo-aligned to the Ensembl Homo sapiens reference transcriptome v86
using kallisto v0.44.0 (Bray et al. 2016). In R, transcripts were collapsed to genes using
Bioconductor tximport (Robinson et al. 2009) and differentially expressed genes were
identified using Limma-Voom (Law et al. 2014, Ritchie et al. 2015). Gene set enrichment
analysis (GSEA) was performed using the GSEA software and the annotated gene sets
of the Molecular Signatures Database (MSigDB) (Subramanian et al. 2005).
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qPCR
RNA concentrations were measured by NanoDrop (ND-1000; Thermo Fisher Scientific,
Waltham, MA) for each sample and an equal amount of cDNA was prepared using
SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific, Waltham, MA). Following
reverse transcription, a 20μL reaction was loaded into a ViiA 7 Real Time PCR system
(Thermo Fisher Scientific, Waltham, MA). The following conditions were used: Initial
incubation 3 min at 95°C, 40 cycles of 95°C for 15 sec and 60°C for 30 sec. A single melt
curve and ΔΔCt method was used to determine relative expression with GAPDH used as
the housekeeping gene. See Table 1 for list of primers.

Western Blot
24 well HCT-8 cultures grown to 60% confluency were infected with 2x10 5 C. parvum
oocysts in RPMI containing 1% serum for the indicated time. Media was removed and
cells were lysed in Pierce TM IP Lysis Buffer (ThermoFisher Scientific, Waltham, MA),
supplemented 1:100 with protease inhibitor cocktail (Sigma St. Louis, MO). Lysates were
incubated on ice 10 minutes, then spun at 20,000 g for 10 min at 4°C. The cleared lysate
was removed and flash frozen. Cleared lysates were thawed on ice and protein
concentration was assessed by BCA (23225, ThermoFisher Scientific, Waltham, MA).
18μg of sample was loaded per well diluted 1:1 with freshly prepared 2X Laemmli Sample
buffer (BioRad Hercules, CA) + -Mercaptoethanol (1:20) (Sigma St. Louis, MO) and
boiled for 10 minutes at 95°C. 20 µL sample was loaded per each lane of an any KD MiniPROTEAN® TGX™ Precast Protein Gel (BioRad Hercules, CA) and run at 150 V for 1
hour. Wet transfer to a 0.45 µm pore size pre-cut Nitrocellulose membrane (ThermoFisher
62

Scientific Waltham, MA) was conducted at 20V for 2.5 hours at room temperature. The
Nitrocellulose membrane was blocked for 1 hour at room temperature using
Intercept®(TBS) Protein-Free Blocking Buffer (LI-COR Lincoln, NE). Primary antibody
was incubated at room temperature for 2 hours in Intercept®(TBS) Protein-Free Blocking
Buffer with 0.01% Tween®20 (Sigma, St. Louis, MO) using STAT1 1:1000 (#14994, Cell
Signaling Technology), phosphor STAT1 Y701 1:1000 (ab29045, Abcam) and alphatubulin 1:5000 (ab7291, Abcam). The membrane was washed 3 times with PBS with
0.01% Tween®20 (Sigma, St. Louis, MO). Secondary antibody was incubated at room
temperature protected from light for 1 hour in Intercept®(TBS) Protein-Free Blocking
Buffer with 0.01% Tween®20 (Sigma, St. Louis, MO) using IRDye® 800CW Goat antiMouse IgG secondary antibody at 1:10,000 (LI-COR Lincoln, NE) and IRDye® 680RD
Goat anti-Rabbit IgG secondary antibody at 1:10,000 (LI-COR, Lincoln, NE). After 3 PBS
+ 0.01% Tween®20 (Sigma, St. Louis, MO) washes, the membrane was imaged on the
Odyssey Infrared Imaging System v3.0 (LICOR, Lincoln, NE).

ELISA
96 well HCT-8 cultures grown to 60% confluency were infected with 25,000 C. parvum
oocysts. At the indicated timepoint post infection, supernatants were removed and spun
at 1,000xg for 10 minutes to pellet debris. Supernatants were frozen at -80°C. IFNβ and
IFNλ protein levels from HCT-8 cultures were measured by Human IFN-beta DuoSet
ELISA (DY814, R&D Systems) and Human IL29/IL28B (IFN-lambda 1/3) DuoSet ELISA
(DY1598B, R&D Systems). Protein levels of IFNλ from intestinal biopsies were measured
by Mouse IL28B/ IFN-lambda 3 DuoSet ELISA (DY1789B, R&D Systems). Protein levels
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of IL-18 from intestinal biopsies were measured by ELISA (BMS618-3, ThermoFisher,
Waltham, MA). Assays were performed according to the manufacturer’s instructions.

Flow sorting of infected cells
HCT-8 6 well cultures were infected with 1x10 6 C. parvum Neon oocysts. 10 hours later,
cells were trypsinized in TrypLE (ThermoFisher), washed with PBS, and passed through
a 40 μm filter. Cells were sorted using a BD FACSJazz Sorter (BD Biosciences).
Uninfected HCT-8 were used to gate on singlets. 10,000 positive cells and 10,000
negative cells were sorted from three independent biological replicates directly into RLT
Lysis buffer (Qiagen).

Ileal biopsy
Three 5mm punch biopsies were taken from the distal small intestine of each mouse.
Punches were incubated in complete RPMI for 18 hours. Supernatants were then used
for ELISA.
For qPCR, punches were placed in RNAlater (Sigma) at 4°C until RNA was extracted
using the RNeasy Mini Kit (Qiagen)

Nanoluciferase Assay
To monitor infection in vivo, 20mg of fecal material was resuspended in 1mL of lysis buffer.
Samples were shaken with glass beads for 5min at 2,000 rpm. Samples were briefly
centrifuged to pellet any floating material and the cleared lysate was mixed 1:1 with
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prepared Nanoluciferase solution (substrate: lysis buffer 1:50). Luminescence was
measured using a Promega GloMax plate reader.
For in vitro assay, 100μL of lysis buffer was added to each well of a 96 well plate and
incubated at room temperature for 5 minutes. Samples were mixed 1:1 with
Nanoluciferase solution and measured as indicated above.

Cytokine neutralization and administration
To neutralize IFNλ, 20μg of Anti IL28A/B (Clone 244716, MAB17892, R&D Systems,
Minneapolis, MN) was infected intraperitoneally one day prior and each day following
infection for the duration.
For administration of Ifnλ2 (250-33, Peprotech, Cranbury, NJ), 1μg, unless otherwise
noted, was injected intraperitoneally daily beginning at 6-8 hours prior to infection and then
each day of the infection.

Histology
Tissue from the lower third of the small intestine was flushed with 10% neutral buffered
formalin (Sigma, St Louis, MO, USA), then ‘swiss-rolled’ and fixed overnight. Fixed
samples were paraffin-embedded, sectioned, and stained with hematoxylin and eosin for
detailed histologic evaluation. Slides were evaluated by a board-certified veterinary
pathologist in a blinded fashion for quantitative measurements of number of parasites,
villus/crypt architectural features, and semi-quantitative scores for villus epithelium lesions
as previously described (Sateriale et al. 2019).

65

PRR agonist screen
Agonists of pattern recognition receptors were purchased from Invivogen. Cells were
seeded into 96 well plates and at 60% confluency, cells were either infected with C.
parvum (25,000 oocysts per well) or treated with an agonist. 10μg/mL LMW Poly (I:C) was
either lipofected or added to the medium. The following agonists were delivered with
Lipofectamine: 5’ppp RNA (10μg/mL), mTriDAP (10μg/mL), HSV60 (5μg/mL), ssPolyU
RNA (10μg/mL), and CpG ODN (5μM). After 24 hours the media was removed for ELISA
and the cells were lysed and RNA extracted (RNeasy Mini Kit, Qiagen).

Statistical Methods
Mean +/- SD are reported. When measuring the difference between two populations, a
standard t-test was used. For datasets with 3 or more experimental groups, a one-way
ANOVA with multiple comparison’s test was used. For datasets with 2 or more
experimental groups and an additional factor of time, a two-way ANOVA with multiple
comparison’s test was used and simple linear regression was used to determine the
goodness of fit curve for host cell killing by C. parvum. P values of less than 0.05 were
considered significant. These tests were performed in GraphPad Prism or in R.

Data Availability
Data are within the manuscript and supporting information files and are accessible through
GEO accession number: GSE185247. All code used to process and analyze the data is
available through Code Ocean: https://doi.org/10.24433/CO.1074647.v1
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Table 1. List of Primers
Name
Sequence
Cp18s F

CTCCACCAACTAAGAACGGCC

Cp18s R

TAGAGATTGGAGGTTGTTCCT

Hs GAPDH F

GCACCACCAACTGCTTAGC

Hs GAPDH R

AGTCTTCTGGGTGGCAGTGA

Hs IFNB F

ttgacatccctgaggagattaagc

Hs IFNB R

ttagccaggaggttctcaacaatag

Hs IFNL1 F

gttcaaatctctgtcaccac

Hs IFNL1 R

ttcagcttgagtgactcttc

Hs IFNL2/3 F

gccaaagatgccttagaagag

Hs IFNL2/3 R

cagaaccttcagcgtcagg

Hs ISG15 F

CCTTCAGCTCTGACACC

Hs ISG15 R

CGAACTCATCTTTGCCAGTACA

Hs ISG56 F

GGATTCTGTACAATACACTAGAAACCA

Hs ISG56 R

CTTTTGGTTACTTTTCCCCTATCC

Hs OASL F

GCAGAAATTTCCAGGACCAC

Hs OASL R

CCCATCACGGTCACCATTG

Mm GAPDH F

TGACCTCAACTACATGGTCTACA

Mm GAPDH F

CTTCCCATTCTCGGCCTTG

Mm Ifnl 2/3 F

agctgcaggccttcaaaaag

Mm Ifnl 2/3 R

tgggagtgaatgtggctcag

PIGP guide 1-F

CACCGGTACTTACTGAAGCCAAATT

PiGP guide 1-R

AAACAATTTGGCTTCAGTAAGTACC

CD151 guide 2F
CD151 guide 2R
B3GAT3 guide
1-F
B3GAT3 guide
1-R
hU6-F

CACCGTTGATGCAGTTCCACTGCTG

Lentiguide seqR
STAT1 cDNA
attB1-F

caaagtggatctctgctgtc

AAACCAGCAGTGGAACTGCATCAAC
CACCGCCAGAGCCCATACCTGGCAT
AAACATGCCAGGTATGGGCTCTGGC
gagggcctatttcccatgatt

GGGGACAAGTTTGTACAAAAAAGCAGGCTCGACCATGTCTCAGTGGTA
CGAACTTCAG
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STAT1 no
STOP attB2-R

GGGGACCACTTTGTACAAGAAAGCTGGGTCCACTTCAGACACAGAAAT
CAACTCAG

TMEM30A diag
1F
TMEM30A diag
1R
TLR3 seq1-F

GACACAGAAAAGGGGAAATGTAAC

TLR3 seq1-R

GTATTGCTGGTGGTGGACAG

TLR7 seq1-F

GATGTCACTCTGGATGTTCC

TLR7 seq1-R

GCTGGTTTCCATCCAGGTAA

STAT2 qPCR F

agccaactgaaagaccagca

STAT2 qPCR R

tgtctccagctgttccaacc

B4GALT7
qPCR F
B4GALT7
qPCR R
MGAT1 qPCR
F
MGAT1 qPCR
R
CD151 qPCR F

GGTGGACCACTTCAGGTTCA

CD151 qPCR R

CATGCCAAAGACCTGCACAC

TMEM30A
qPCR F
TMEM30A
qPCR R
CSK qPCR F

CTCGGAGACCGGATAACACG

CSK qPCR R

GTATGGGTGCAAGGAGAGGG

RALGAPB
qPCR F
RALGAPB
qPCR R
STAT1 guide 2F
STAT1 guide 2R
STAT2 guide 3F
STAT2 guide 3R
TMEM30A
guide 2-F
TMEM30A
guide 2-R

AGATTCAGCTGCTGGGCTC

GATGCTTAATACTGGACACCTATAGAG
GTAAGGAAGGACTCGTGCAT

GTCCAGCTCCTCGTTGAGAG
GCCTGGATTGCGACCCG
AGAACTGGCCCATCTGTCTTG
GTGGCAGCAACAACTCACAG

AAACACGTTGCCCTCGATCT
CGCGACGTTCCAAAATCGAA

ACCTTTGCAAGGCCAGAGAG
CACCGTCCCATTACAGGCTCAGTCG
AAACCGACTGAGCCTGTAATGGGAC
CACCGATCATCTCAGCCAACTGGGT
AAACACCCAGTTGGCTGAGATGATC
CACCGCATTTATTACAGGGACTGGA
AAACTCCAGTCCCTGTAATAAATGC
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STAT1 guide 2
seq-F
STAT1 guide 2
seq-R
CD151 guide 2
seq-F
CD151 guide 2
seq-R
IFNLR1 guide 1
seq-F
IFNLR1 guide 1
seq-R
B3GAT3 guide
1 seq-F
B3GAT3 guide
1 seq-R

CCTTGTTAACAGTTTGCCAGC
CTCATTTACTGGGTACTGGGCA
TGAACACGGAGCTCAAGGAG
AGATATTGGAGGCGTGTCCC
GGATGGCATGAGAGAAGGCA
ACTGCCAGAAGTCAGGAGTG
ACGGCAGAAGGATCTGAGGATT
TTTCTTGCCAAACGGTCCCTAAG
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CHAPTER 3: A Genetic Screen Identifies Host Genes Important for
Susceptibility to Cryptosporidium and Host Cell Death

70

Abstract
Cryptosporidium is a leading cause of severe diarrhea and diarrheal-related death
in children worldwide. As an obligate intracellular parasite, Cryptosporidium relies on
intestinal epithelial cells to provide a niche for its growth and survival, but little is known
about the contributions that the infected cell makes to this relationship. Here, we
conducted a genome-wide CRISPR/Cas9 knockout screen to discover host genes
required for Cryptosporidium parvum infection and/or host cell survival. Gene enrichment
analysis indicated that the host interferon response, glycosaminoglycan (GAG), and
glycosylphosphatidylinositol (GPI) anchor biosynthesis are important determinants of
susceptibility to C. parvum infection. Several of these pathways are linked to parasite
attachment and invasion and C-type lectins on the surface of the parasite. We also identify
the tetraspanin CD151 as a potential invasion factor localized to the site of infection. Our
work identifies several host proteins that may play a role in Cryptosporidium infection and
provide new insight into the interaction between this parasite and its epithelial host cell.
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Introduction
Cryptosporidium is a leading cause of diarrheal disease. In the United States, this
apicomplexan parasite accounts for more than half of all waterborne disease outbreaks,
and infection can be life-threatening in individuals with compromised immune function
(Colford et al. 1996, Hlavsa et al. 2018). Globally, the burden of this disease rests
disproportionally on children under the age of two and the parasite is an important
contributor to early childhood mortality (Kotloff et al. 2013). Children can experience
multiple episodes of infection, however, parasite and disease burden diminish over
successive infections and non-sterile immunity protects children from severe illness as
well as stunting (Kabir et al. 2021).
Cryptosporidium infection is typically restricted to the small intestine, but infection
of the biliary tree and respiratory involvement has also been reported (Vakil et al. 1996,
Sponseller et al. 2014). Within the intestine, the infection is limited to epithelial cells in
which the parasite occupies an intracellular but extra-cytoplasmic niche at the brush
border. A number of cytoskeletal and membranous structures separate the
parasitophorous vacuole from the bulk of the infected enterocyte (Current and Reese
1986, Elliott and Clark 2000). While reorganization of the actin cytoskeleton is one of the
most prominent changes in host cell morphology, infection is also known to interfere with
the composition and function of tight junctions, to induce tyrosine phosphorylation, and to
activate PI3K signaling (Chen et al. 2003, Kumar et al. 2018). Recent studies have
identified parasite proteins that are injected into the host cell during and after invasion
(Dumaine et al. 2021, Guérin et al. 2021) but we know very little about the specific
components of the host cell that shape host-parasite interaction for Cryptosporidium.
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Here, we used a CRISPR-Cas9 knockout screen to identify host genes that impact
host cell survival during Cryptosporidium infection. The screen revealed the importance of
several pathways, with IFN signaling, sulfated GAGs, and GPI anchor synthesis most
prominent. Further work will elucidate the roles that our candidates play during
Cryptosporidium infection.

Results

A screen for host genes that impact Cryptosporidium infection and host cell
survival
How Cryptosporidium interacts with its host cell is poorly understood. The parasite
is thought to rely on pathogenesis factors exposed on its surface or secreted during and
after invasion (Chen et al. 2004, Guérin and Striepen 2020), however, host proteins are
likely to play important roles in this interaction as well. To identify such host factors, we
conducted an unbiased genetic screen. Since Cryptosporidium infection is limited to
epithelial cells, we chose to screen in HCT-8 cells, a colon-derived human
adenocarcinoma cell line widely used for experiments with this parasite (Upton et al.
1994). In this in vitro culture system, parasites can only be propagated for 72 hours and
then growth ceases. First, we measured the survival of HCT-8 cells over a range of
infection conditions and found C. parvum to induce host cell death in a dose-dependent
fashion over the 72 hours (Figure 3.1A). We chose to move forward with a 90% kill dose
to impose strong selection for loss of function in genes required for parasite growth or cell
death as part of the host response to infection. Next, we generated clonal HCT-8 cell lines
73

that stably express Cas9 (Sanjana et al. 2014) and assessed activity in each clone using
an EGFP reporter assay (Doench et al. 2014). Briefly, Cas9 expressing cells were
transfected with a lentiviral vector encoding EGFP as well as a single guide RNA (sgRNA)
targeting the EGFP gene and analyzed by flow cytometry. Cells with Cas9 activity show
reduced fluorescence when compared to the parental cell line and are shown normalized
to a control cell line expressing no EGFP (Figure 3.1B). Clones C, I, and K showed high
activity and served as three independent biological replicates in the subsequent screen.
Using the Brunello lentiviral CRISPR library, we targeted the full complement of human
protein-coding genes with four sgRNAs each in addition to controls (Doench et al. 2016)
for a total of 77,441 sgRNAs. 108 cells of each clone were transduced with the library at
an MOI of 0.4 to ensure each cell received only one sgRNA. Following seven days of
puromycin selection, cells were expanded to 4 T175 flasks, achieving roughly 500-fold
coverage, and infected with C. parvum at a 90% kill dose. After 72 hours, the media was
changed, and surviving cells were allowed to expand. Cells were exposed to C. parvum
for a total of three rounds of infection and expansion to enrich for resistant host cells
(Figure 3.1C). Genomic DNA was extracted from the input population as well as following
each round of infection.
We also evaluated the phenotypic consequences of the screen. Following
infection, we measured percent killed as described above. We found that in the pre-screen
population an average of 80% of HCT-8 were killed compared to 23% of cells in the postscreen population (Fig 3.1D). Next, we infected the pre-screen and post-screen population
with Nanoluciferase expressing parasites and measured luminescence as a readout for
infection at 3,6,12, and 24 hours post infection. At all time points assessed, the post74

screen population showed significantly lower infection than the pre-screen population
(Two-way ANOVA, p value < 0.0001, Fig 3.1E). We also assessed infection by microscopy
at 48 hours post-infection. 96 well cultures infected with increasing doses of C. parvum
oocysts showed a highly significant defect in infection of the post-screen population (Twoway ANOVA, p value < 0.0001, Fig 3.1F). We conclude that the genome-wide screen
selected for cells resistant to C. parvum infection and to host cell death upon infection.

Figure 3.1 A genome-wide screen selects for cells resistant to infection and infectioninduced death
To identify host genes required for Cryptosporidium infection we performed a genome-wide
knockout screen we then phenotypically characterized the output population. (A) HCT-8 cells
infected with increasing numbers of C. parvum oocysts are killed in a dose-dependent manner.
Host cell viability was assessed by Trypan Blue exclusion. R2=0.7522 (B) Cas9 activity in different
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clones of Cas9 expressing HCT-8 cells assessed by flow cytometry normalized to a positive control
set to 100 percent. (C) Schematic of CRISPR screen using C. parvum induced host cell death as
selection. (D) The population of Cas9-Clone K expressing cells transduced with the library prior to
the screen were compared to the population following the last round of selection. Cells were
infected with C. parvum for 72 hours. Host cell viability was assessed by Trypan Blue exclusion.
n=3 (E) The pre- and post-screen populations were infected with Nanoluciferase expressing
parasites for the indicated time points. Parasite growth was measured by Nanoluciferase assay.
Two-way ANOVA p < 0.001 **** n=3 (F) The pre- and post-screen populations were infected with
increasing numbers of oocysts for 48 hours and parasite growth quantified by microscopy, VVL
assay. Two-way ANOVA p < 0.001 **** n=1

Genetic screening reveals genes required for infection and host response
Deep sequencing of the integrated sgRNAs and comparison with the input
population revealed the progressive enrichment of a subset of sgRNAs with each round
of infection (Figure 3.2A). Using model-based analysis of genome-wide CRISPR/Cas9
knockout (Li et al. 2014), we identified 35 significantly enriched genes (FDR < 0.05, Figure
3.2B). Among these genes, gene set enrichment analysis (GSEA) reveals three distinct
pathways each supported by multiple genes (Fig 3.2B). IFNAR2, IFNLR1, IL10RB, IRF9,
STAT1, STAT2, JAK1, and TYK2 cluster within the pathway of interferon (IFN) signaling.
B3GAT3, B4GALT7, EXT1, SLC35B2 are genes encoding enzymes in the biosynthesis of
sulfated glycosaminoglycans (GAG). In addition, the screen selected for nine enzymes
required for glycosylphosphatidylinositol (GPI) anchor biosynthesis (GPAA1, MGAT1,
PGAP2, PIGA, PIH, PIGL, PIGO, PIGP, PIGT). Beyond these pathways, a number of
genes were significantly enriched that were not members of a particular pathway or
represented the single representative of a pathway. Among those with known molecular
function were accessory proteins to ATP flippase (TMEM30A), tyrosine protein kinases
(CSK), GTPase activators (RALGAPB), G protein coupled receptor signaling regulators
(PDCL), granule biogenesis proteins (NBEAL2), transcriptional activators of apoptosis
(RRP1B),

dehalogenases (IYD), tetraspanins (CD151), fibronectin domain proteins
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(FNDC3B), chaperones (UNC93B1 and HSP90B1), transcription factors (OLIG1), serine
protease (TMPRSS3), and peptide hormone receptors (NPR3).
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Figure 3.2 A genome-wide screen reveals genes required for susceptibility to
Cryptosporidium infection and host cell death

78

Analysis of the genome-wide knockout screen using Cryptosporidium infection as a selective agent
(A) Bubble plot of Cas9 expressing Clone K screen showing enrichment of specific genes with each
round of selection by C. parvum infection. Each bubble represents a human gene and the size of
bubbles corresponds to fold change. y-axis is the inverse of the adjusted p value. (B) GSEA plot of
“type I interferon signaling pathway” enriched following screen. Net enrichment score (NES) = 2.1,
p value<0.05 (C) GSEA plot of “Glycosylphosphatidylinositol (GPI)-anchor biosynthesis” pathway
enriched following screen. Net enrichment score (NES) = 2.67, p value<0.05 (D) GSEA plot of
“Glycosaminoglycan (GAG) biosynthesis” pathway enriched following screen. Net enrichment
score (NES) = 2.27, p value<0.05 (E) Bubble plot of a concatenation of Clones I and K comparing
input to the final selection for 1000-fold coverage. The top 35 genes were colored and grouped
based on function. Size of bubbles corresponds to fold change.

To validate the screening results, HCT-8 cells were transduced with siRNA
targeting a subset of the top candidates for 24 hours prior to infection. Knockdown was
assessed by qPCR and a decrease in transcripts was found to be typically 30% or greater.
48 hours after C. parvum infection, we assessed host cell viability using the MTT assay.
We found that many candidates when knocked down, show increased resistance to cell
death, no difference was noted in the absence of infection (Figure 3.3).

Figure 3.3 Impact of siRNA knockdown of screening hits on host cell survival upon C.
parvum infection.
We used siRNA treatment to knockdown transcripts of genes identified in our screen and assessed
host cell viability following infection. (A) Relative expression of genes targeted for knockdown
normalized to the scrambled (scr) siRNA control. n=2 (B) Knockdown of top candidates does not
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affect host cell viability in the absence of infection. MTT assay normalized to uninfected scrambled
(scr) siRNA control. n=2 (C) Knockdown of candidates leads to an increase in host cell viability
during C. parvum infection. MTT assay normalized to uninfected scrambled (scr) siRNA control. *
p <0.05 ** p< 0.01*** p <0.001 n=2

Inhibition of kinases of interferon signaling pathway reduces infection
The pathway of IFN signaling was highly enriched by our screen. Type I and type
III IFNs are induced in response to primarily viral infections and go on to induce the
expression of hundreds of interferon stimulated genes (ISGs). The genes identified in our
screen include those required for the response to IFN upstream of the transcriptional
response induced (Fig 3.4A). In fact, no ISGs were enriched by our screen.
We generated cell lines with targeted disruption of single genes in the IFN signaling
pathway. Disruption of IFNL1 did not lead to a decrease in parasite infection (Fig 3.4C).
In contrast, knockout of IRF9, STAT1 and STAT2 all led to a significant decrease in
parasite infection (One-way ANOVA, Fig 3.4C). Unfortunately attempts to complement the
observed phenotype in STAT1 KO cells were unsuccessful (Fig 3.4D) leaving us unable
to conclude whether the loss of infectivity observed was specifically due to the loss of the
targeted gene.
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Figure 3.4 IFN signaling may play a role during C. parvum infection
(A) The pathway of type I and III interferon signaling. Genes enriched by the screen are highlighted.
(B) Sequencing of loci targeted for CRISPR-Cas9 mutagenesis. The sgRNA and the PAM site are
indicated. The wild type allele is shown above the sequence of the targeted alleles. (C) 96 well
cultures of Cas9 control cells or specified knockout cells were infected with 10,000 Nanoluciferase
expressing C. parvum. Luminescence was measured at 48 hours post infection One way ANOVA
*** p <0.001 **** p <0.0001 n=3 (D) 96 well cultures of Cas9 control cells, STAT1 KO, or STAT1

81

KO cells transfected with STAT1 addback were infected with 10,000 Nanoluciferase expressing C.
parvum. Note that addition of STAT1 to knockout cells does not rescue phenotype of reduced
infection. n=3

To examine the effect of the interferon signaling pathway on infection in the
absence of Cas9 mutagenesis, we treated HCT-8 cultures with inhibitors of the Janus
kinases, JAK1 and TYK2. In the presence of Jak inhibitor, infection of Toxoplasma gondii
in HCT-8 cultures was not perturbed (Fig 3.5A), however, C. parvum infection was
significantly reduced at all concentrations of Jak inhibitor tested (One-way ANOVA, Figure
3.5B). Peculiarly, the greatest reduction in infection was observed at 2x IC 50 of TYK2 which
was not the highest concentration tested. Tyrosine kinases have been implicated in the
growth of Plasmodium and Toxoplasma (Lim et al. 2012) but at these nanomolar
concentrations, the Jak inhibitor should have very few off-target effects.

Figure 3. 5 Inhibition of kinases of the interferon signaling pathway reduces C. parvum
infection
(A) HCT-8 were infected with TdTom RH T. gondii tachyzoites. Cells were pretreated with Jak
inhibitors at the given concentration for 3 hours prior to infection. The red fluorescence was
measured each day for 7 days post infection. The total red fluorescence for the infection is shown.
(B) HCT-8 were infected with Nanoluciferase expressing C. parvum for 48 hours. Cells were
pretreated with Jak inhibitors at the given concentration for 3 hours prior to infection. Parasite
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growth was assessed by Nanoluciferase assay. n=3 One-way ANOVA with Dunnett’s multiple
comparisons * p <0.05 ** p <0.01 *** p <0.001 **** p <0.0001.

GPI anchor biosynthesis
Seven genes in the pathway of biosynthesis of GPI anchors were highly enriched
by our screen. GPI-anchored proteins are anchored to the outer leaflet of the plasma
membrane and are frequently associated with “lipid rafts” or microdomains of the
membrane. The GPI anchor is assembled in the ER lumen and Golgi where a
phosphatidylinositol is sequentially glycosylated prior to C-terminal addition of the
glycolipid to proteins through peptide linkage to the terminal ethanolamine (Fig 3.6A).
Attempts to generate single gene knockouts in this pathway were unsuccessful, each
resulting in a heterozygous deletion, disruption of PIGP is shown as a representative (Fig
3.6B). Of note, the enzyme that flips the glucosaminyl PI into the ER lumen has not been
identified and in our screen an accessory protein to ATP flippases, TMEM30A, was also
highly enriched. We were unable to disrupt the TMEM30A locus with two different sgRNAs
and multiple transfections attempted. Further work is required to understand the important
role GPI anchored proteins play in Cryptosporidium infection.
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Figure 3.6 GPI anchor biosynthesis
(A) GPI anchors are synthesized in the ER and Golgi through a series of glycosylation steps
involving several protein complexes. Genes enriched by the screen are highlighted (B) Sequencing
of PIGP locus targeted for CRISPR-Cas9 mutagenesis. The sgRNA and the PAM site are indicated.
The wild type allele is shown above the sequence of the targeted alleles. Note the presence of one
wild-type allele and one disrupted allele.

GAG biosynthesis
Glycosaminoglycans have been implicated in the attachment and invasion of
Cryptosporidium (Cevallos et al. 2000, Hashim et al. 2006, Edwinson et al. 2016). Sulfated
GAGs such as heparan sulfate, were shown to interact with a C-type lectin identified on
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the surface of Cryptosporidium (Ludington and Ward 2016). The enrichment of five genes
involved in the synthesis of GAGs supports the role of host GAG biosynthesis in
Cryptosporidium infection.

B4GALT7 and B3GAT3 are both localized to the Golgi, and each catalyze a step
in the synthesis of the tetrasaccharide linker region that is attached to a serine residue of
the modified protein (Fig 3.7A). EXT1 is specific to the synthesis of sulfated heparan
proteoglycans as it catalyzes the formation of the repeating disaccharide region. SLC35B2
imports the sulfate donor, 3’-phosphoadenosine-5’-phosphosulfate (PAPS), that is
required for sulfation of glycans in the Golgi. Disruption of SLC35B2 reduces sulfation of
GAGs and N-glycans in human colon cell lines (Kamiyama et al. 2010). MGAT1 is required
to form complex N-linked glycans and disruption of this gene limits glycosylation to the
production of early intermediates (Byrne et al. 2018).
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Figure 3. 7 GAG biosynthesis may play a role during C. parvum infection
(A) GAG biosynthesis occurs in the Golgi to post-transcriptionally modify glycoproteins. Genes
enriched by the screen are highlighted. (B) Sequencing of loci targeted for CRISPR-Cas9
mutagenesis. The sgRNA and the PAM site are indicated. The wild type allele is shown above the
sequence of the targeted alleles. (C) 96 well cultures of Cas9 control cells, B3GAT3 KO, or either
cell line transfected with B3GAT3 addback were infected with 10,000 Nanoluciferase expressing
C. parvum. Note that addition of B3GAT3 to control cells showed an increase in infection. Note that
addition of B3GAT3 to knockout cells does not rescue phenotype of reduced infection. n=3

B3GAT3 was disrupted in HCT-8 cells with a 5bp deletion in either allele upstream
of the PAM site (Fig 3.7B). Infection of B3GAT3 KO cells revealed a significant defect in
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parasite growth (Fig 3.7C). Unfortunately, this defect could not be rescued with addition
of functional B3GAT3. Of note, overexpression of B3GAT3 in Cas9 control cells alone
increased parasite infection.

CD151 is a potential invasion factor for Cryptosporidium
We expected to find genes involved in any process from invasion to egress of the
parasite. We sought to examine a role for any of our top candidates in invasion. An
antibody for CD151 was available and suitable for immunofluorescence, we thus
visualized localization of CD151 at 1-hour post-infection. CD151 localized to the site of
newly invaded parasites (Fig 3.8A). We generated CD151 knockout cells with one allele
encoding a 17bp deletion and the second allele having an 18bp deletion (Fig 3.8B). While
the 18 bp deletion did not result in a frameshift it does remove the conserved CCG motif
of the large extracellular loop of the tetraspanin likely disrupting proper protein folding.
Infection was significantly reduced in CD151 KO cells (Fig 3.8C). Immunofluorescence
assay of the CD151 KO cells showed no detectable CD151 (Fig 3.8D). We also observed
a change in morphology in the CD151 KO. The cells were rounded and appeared to be
less attached to neighboring cells based on actin labeling. These morphological
characteristics were common among many of the knockout cell lines generated. It is thus
difficult for us to distinguish specific effects on parasite invasion and growth from more
general effects, due to overall changes in parasite morphology due to the inability to
complement phenotypes.
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Figure 3.8 CD151, an invasion factor for Cryptosporidium
(A) Immunofluorescence of HCT-8 infected with C. parvum at 1-hour post-infection. C. parvum
(red), CD151 (gray), actin (green) Hoechst label nuclei. Scale bar 10μm in top panel, scale bar 5μm
in bottom panel (B) Sequencing of CD151 locus targeted for CRISPR-Cas9 mutagenesis. The
sgRNA and the PAM site are indicated. The wild-type allele is shown above the sequence of the
targeted alleles. (C) 96 well cultures of Cas9 control cells or CD151 KO cells were infected with
10,000 Nanoluciferase expressing C. parvum. Luminescence was measured at 48 hours postinfection. (D) Immunofluorescence of uninfected Cas9 HCT-8 or CD151 KO cells. CD151 (green)
actin (red) Hoechst label nuclei. Note the absence of CD151 signal in the KO cell line
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Discussion
We conducted a whole genome knockout screen to identify human genes that
influence Cryptosporidium infection and host survival. We identified 35 genes with high
confidence, and they implicate multiple pathways.

Parasite attachment and invasion
Five of the genes enriched in our screen encode steps in the synthesis of
glycosaminoglycans. This provides further support for the notion that interactions between
a parasite C-type lectin and host glycosaminoglycans are critical to parasite binding and
invasion (Ludington and Ward 2016). GPI anchor synthesis is also highly prominent
among the enriched genes. GPI anchored proteins are preferentially targeted to the apical
membrane of polarized cells (Lisanti et al. 1990), the membrane used by the parasite to
invade. GPI anchored proteins are thus exposed to the parasite. Among them are
glypicans which serve as the platform of apically displayed membrane-associated
glycosaminoglycans in the intestine (Filmus et al. 2008). GPI anchored proteins are also
associated with microdomains which have been suggested to be the site of invasion for
Cryptosporidium (Nelson et al. 2006). The screen also identified the tetraspanin CD151
and in infected cells, this host protein is recruited to the host-parasite interface. CD151 is
critical to the uptake and intracellular trafficking of human cytomegalovirus and
pappilomavirus (Fast et al. 2017), and the related protein CD81 is required for the invasion
of hepatocytes by Plasmodium sporozoites (Silvie et al. 2003). Tetraspanins act as
scaffolds forming membrane microdomains that mediate adhesion, signaling, fusion and
fission, and CD151 is well known for its role in integrin signaling (Termini and Gillette
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2017). Candidate FNDC3B contains a fibronectin type III domain involved in interactions
with integrins and knockdown of this gene in HCT8 leads to a decrease in phosphorylation
of PI3K (Li et al. 2020). Polymerization of host actin is a prominent feature of
Cryptosporidium invasion and host modification and there is evidence for parasite
engagement of host integrins and PI3K signaling (Chen et al. 2004, Zhang et al. 2012) in
this context.

Cellular signaling and membrane trafficking
The screen also identified the kinase CSK, a negative regulator of Src family
kinases. c-Src kinase was shown to play an important role in host actin polymerization
during Cryptosporidium infection (Chen et al. 2003). Traditionally, this has been viewed
as aiding parasite infection; however, recent studies may suggest a more complex picture
in which the cortical cytoskeleton might also act in host defense (Rauch et al. 2017, Guérin
et al. 2021). Src family kinases are also critical to pattern recognition receptor-mediated
detection of pathogens leading to the production of interferons and CSK is critical to tune
this response (Johnsen et al. 2009, Nousiainen et al. 2013, Li et al. 2017).
Multiple hits may impact membranes and their trafficking including NBEAL2,
TMEM30A, and RALGAPB. RALGAPB is an inhibitor of the small GTPases RalA and
RalB, which in turn activates the exocyst complex. In epithelial cells, the exocyst is critical
to exocytosis as well as the dynamic remodeling of the actin cytoskeleton (Shirakawa and
Horiuchi 2015). RalA activity is required for membrane recruitment to the Salmonella
typhimurium infection site (Nichols and Casanova 2010). TMEM30A is an essential
binding partner of P4 type ATPase flippases and directs the trafficking of the catalytic
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subunits from the trans-Golgi to the plasma membrane (Bryde et al. 2010). Deletion of
TMEM30A leads to defects in both endocytosis and exocytosis due to a loss of the
asymmetric distribution of phospholipids across the plasma membrane (Yang et al. 2021).
NBEAL2 is required for the formation of secretory granules in a variety of cells (Cullinane
et al. 2013). At least two hits act on nucleotide signaling, PDCL or phosducin-like Gprotein, is a chaperone of G-protein beta gamma dimers (Lukov et al. 2005) and
erythrocyte G-proteins have been shown to play a role in Plasmodium falciparum invasion
(Harrison et al. 2003). NPR3 is a G-protein coupled receptor that binds polypeptide
hormones termed natriuretic peptides. Binding to this receptor inhibits adenylate cyclase
and decreases cAMP (Anand-Srivastava et al. 1990).

Innate Immunity
IFN signaling was the most prominent pathway to emerge from our screen.
Components of the response to type I and III IFN including receptors, receptor tyrosine
kinases, and the transcription factors were all enriched. Notably no ISGs downstream of
initiation of transcription were identified. The Jak inhibitor data shows a Cryptosporidium
specific effect of IFN signaling during infection that warrants further study.
Some genes appear to be involved in PRR signaling. HSP90B1, the ER paralog
of the cytosolic HSP90 has been extensively studied for its roles in innate immunity,
primarily the unconventional secretion of IL-1 family cytokines (Zhang et al. 2020) as well
as its action as a chaperone for cell surface TLRs (Yang et al. 2007). UNC93B1 is also a
chaperone for TLRs and is required to stabilize the nucleic acid sensing TLRs (Pelka et
al. 2018).
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Two genes may be involved in host cell death. Loss of TMPRSS3 leads to an
increase in cleaved Caspase 3 expression, a hallmark of apoptosis (Tang et al. 2019).
RRP1B expression is induced by E2F1 activation and by a number of DNA-damage
inducing chemicals (Paik et al. 2010), and it induces the expression of a subset of proapoptotic genes.
The genes and pathways identified here provide new avenues for exploration of
the host processes necessary for successful infection by Cryptosporidium.
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CHAPTER 4: TLR3 dependent recognition of Cryptosporidium
induces a host protective type III interferon response
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Abstract
Cryptosporidium is an obligate intracellular protozoan parasite and the second
leading cause of severe diarrhea and diarrheal-related death in children worldwide.
Despite a massive impact on public health, little is known about the host response to
Cryptosporidium. Transcriptional profiling of human intestinal epithelial cells infected with
C. parvum revealed an innate interferon signature. Evaluation of transcript and protein
induction of interferons revealed a pronounced type III interferon response to
Cryptosporidium in human cells as well as in mice. Treatment of mice with IFNλ reduced
parasite burden and protected immunocompromised mice from severe outcomes
including death, and this required STAT1 signaling in the enterocyte. Initiation of this type
III interferon response was dependent on sustained intracellular growth and mediated by
the pattern recognition receptor TLR3. We conclude that host cell-intrinsic recognition of
Cryptosporidium results in IFNλ production critical to early protection against this infection.
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Introduction
It is well established that T cells are critical to protection from and the resolution of
infection with Cryptosporidium (Ungar et al. 1991). The production of interferon gamma
(IFNγ) is recognized to be one of the essential functions of T cells during Cryptosporidium
infection (Chen et al. 1993), but T cells are not the only source of IFNγ (Pollok et al. 2001,
Barakat et al. 2009, Gullicksrud et al. 2021). Numerous other chemokines and cytokines
produced by the enterocyte including IL-8, IL-18, TGFβ, and RANTES and type one and
three interferons have been noted as well (Laurent et al. 1997, Maillot et al. 2000, Barakat
et al. 2009, Ferguson et al. 2019, Sateriale et al. 2021). These can act directly on
enterocytes and/or stimulate responses by proximal immune cells in the intestinal
epithelium and adjacent tissues leading to the enhanced production of IFNγ, among other
responses. IL-18 was shown to be produced by the enterocyte and to signal to ILC1s
promoting IFNγ production (Gullicksrud et al. 2021). New in vitro enteroid models of
infection have also revealed the presence of a type I IFN response through RNA
sequencing (Heo et al. 2018, Nikolaev et al. 2020). Additionally, type III interferon (IFNλ)
production has been observed in response to C. parvum infection in neonatal piglets and
neonatal mice (Ferguson et al. 2019). Type III interferons, the most recently discovered
members of the cytokine family, were shown to play unique roles at mucosal sites that
could not be compensated for by type I interferons (Pott and Stockinger 2017) making
their role during Cryptosporidium infection of particular interest.
In our work, we found robust production of type III but not type I interferon in human
host cells triggered by infection with C. parvum. This response required live infection and
was initiated in infected cells. We did not identify any protective role for IFNλ in vitro
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therefore we utilized mouse models of infection. In vivo experiments showed IFNλ to limit
parasite growth an effect that was independent of the presence of IFNγ. Exogenous IFNλ
treatment was even protective in severely immunocompromised mice such as Rag2-/-, and
Rag2-/-Il2rg-/-. We investigated the molecular recognition mechanism that leads to this
response and studied its impact on the infection. Thus, we elucidate a mechanism of cellintrinsic recognition and control of Cryptosporidium.

Results
Cryptosporidium parvum infection induces an interferon response
The critical role of IFNγ is well documented in humans (Gomez Morales et al. 1996)
and mice (Ungar et al. 1991) and there are also reports of Cryptosporidium associated
induction of type I and III interferons (Barakat et al. 2009, Heo et al. 2018, Ferguson et al.
2019). To examine the epithelial cell response to C. parvum, we infected 6 well cultures
of HCT-8 cells with 100,000 oocysts and performed RNAseq. 1600 genes were
differentially expressed (1.5-fold; adjusted p value < 0.05) by 48 hours post-infection,
compared to naïve cells (Fig 4.1A). The majority of differentially expressed genes were
upregulated in the infected population compared to the uninfected control (689 genes were
downregulated). GSEA identified significant enrichment of the interferon signaling
pathway in infected cultures compared to uninfected controls (Fig 4.1B). Other strongly
enriched pathways are related to interferon signaling, such as REACTOME: Antiviral
Mechanism by IFN Stimulated Genes.
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Figure 4.1 Cryptosporidium infection generates a type III interferon response in human
intestinal epithelial cells
We examined the response to C. parvum infection in HCT-8 to determine which specific interferons
were induced. (A) HCT-8 cultures were infected with C. parvum oocysts, and RNA was isolated
48 hours post infection from 3 biological replicates and matched uninfected controls. Volcano plot
showing differentially expressed genes between uninfected and infected HCT-8 (n=3, biological
replicates per group). Genes in red are part of the “REACTOME: Interferon Signaling” signature.
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(B) GSEA plot of “REACTOME: Interferon Signaling” signature identified at 48 hours post-infection.
Closed circles represent genes that make up the core enrichment of the signature. Net enrichment
score=3.04, p value <0.0001 (C) 96 wells HCT-8 cultures were infected with 25,000 C. parvum
oocysts for 12-72 hours. Transcript abundance of three representative interferons stimulated genes
(ISGs) measured by qPCR is shown over a time course of C. parvum infection (n=3) (D)
Immunoblot showing presence of phospho STAT1 and total STAT1 in uninfected cultures and
following C. parvum infection. Treatment with IFNλ is used as a control for induction of
phosphoSTAT1. One representative of 2 biological replicates is shown. (E) Samples as in (C).
Induction of type I (IFNβ) and type III interferon (IFNλ) transcripts as assessed by qPCR. Note peak
of IFNL1: 35-fold, IFNL2/3:1200-fold at 48 hours while peak IFNB: 4-fold at 72 hours. n=3 (F)
Protein levels of type I and type III interferons as assessed by ELISA. Samples as in (C, E) At 48
and 72 hours post-infection, the difference between IFNβ and IFNλ was highly significant. Two-way
ANOVA with Dunnett’s multiple comparisons **** p <0.0001. n=3 (G) Relative abundance of C.
parvum ribosomal RNA transcripts normalized to host GAPDH. n=3

To validate the observed interferon signature and to establish kinetics, we next
conducted a qPCR time course experiment for three selected interferon stimulated genes
(ISGs) over 72hours of C. parvum infection to determine when the interferon response is
initiated. We infected 96-well cultures with C. parvum and isolated RNA at 0, 12, 24, 48,
and 72 hours post-infection. ISG transcripts were increased in the first sample taken at 12
hours post-infection and peaked at 72 hours (Fig 4.1C). Binding of interferons to their
receptors initiates an intracellular signaling cascade that culminates in the phosphorylation
of the transcription factor STAT1 leading to transcription of ISGs. We, therefore, assessed
STAT1 phosphorylation by Western Blot in whole cell lysates using a modification specific
antibody. Phosphorylation of STAT1 was not detectable in uninfected cells but was
observed as early as 12 hours post-infection (Fig 4.1D). We also observed an increase in
total STAT1 protein at 24 hours post-infection indicating that STAT1 itself was induced by
the infection, this is consistent with its classification as an ISG. We conclude that C.
parvum infection induces a strong interferon response in HCT-8 cells.
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Cryptosporidium infection preferentially induces a type III interferon response
Next, we asked which interferon was responsible for the response observed.
There are three major interferon types; type II interferon, IFNγ, is only produced by certain
lymphocytes and thus absent from our cultures. In contrast, type I interferons, most
prominently IFNα and IFNβ, and type III interferons, IFNλ 1-4, are known to be produced
by epithelial lineages including the HCT-8 cells used here (Bierne et al. 2012). Our GSEA
analyses found enrichment signatures for type I and type III interferon in infected cultures,
but because both types act through the same intracellular signaling cascade, it is difficult
to distinguish between them by the genes they induce (Crotta et al. 2013). To determine
which types of interferons are expressed - simultaneously or individually - in response to
C. parvum, we measured the transcript abundance of IFNB, IFNL1, and IFNL2/3 by qPCR.
IFNB transcripts did not increase at early time points and remained comparably low at 72
hours (4-fold, Fig 4.1E). In contrast, at 12 hours, the first time point sampled, type III
interferon transcripts were already markedly elevated. Type III interferon transcripts
peaked at 48 hours (IFNL1: 35-fold, IFNL2/3:1200-fold). We also performed enzymelinked

immunosorbent

assays

(ELISA) to

directly

measure

protein

levels

for IFNβ and IFNλ. Only modest amounts of IFNβ were detectable, peaking at 48 hours
post-infection (185 pg/mL). IFNλ production was detected as early as 24 hours postinfection and continued to increase until 72 hours, exceeding IFNβ levels by two orders of
magnitude (16,029 pg/mL, p <0.0001, Two-way ANOVA, Fig 4.1F). The kinetics of the
induction of IFNλ protein followed that of parasite replication, with a large increase
between 24 and 48 hours, when the parasites were actively replicating, and a plateau
between 48 and 72 hours when parasites terminally differentiate to gametes and growth
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ceases (Fig 4.1G and (Tandel et al. 2019)). Taken together, these experiments
demonstrate that type III, rather than type I interferons are preferentially induced by C.
parvum infection in HCT-8 cells.

Live C. parvum infection is required to induce type III interferon production
A variety of pathogen associated molecular patterns (PAMPs) have been shown
to induce a type III interferon response including many bacterial proteins, glycans, and
lipids (Odendall et al. 2017). Oocysts used in our experiments were isolated from the feces
of cows or mice; therefore, we considered that inadvertent inoculation of cultures with
bacterial PAMPS rather than C. parvum infection may drive IFNλ production. To test this,
we heated oocysts to 95°C for 10 min prior to adding them to cells. This kills the parasite
but does not inactivate LPS (Yoshimura et al. 1999). Heat-killed parasites failed to induce
IFNλ at any time point assessed, and at 72 hours post-infection, the difference in IFNλ
production compared to live controls was highly significant (Fig 4.2A, p < 0.0001, Twoway ANOVA). Consistent with the lack of IFNλ production, we did not observe
phosphorylation of STAT1 in cultures inoculated with heat-killed parasites (Fig 4.2B). To
further assess the importance of parasite replication for interferon induction, we used
nitazoxanide, the only currently FDA-approved drug for the treatment of Cryptosporidium
infection. Treatment of cultures led to a 35-fold decrease in parasite infection as assessed
by qPCR (Fig 4.2C). In the nitazoxanide treated infected cultures, IFNλ induction was no
longer observed (Fig 4.2D, p < 0.05, One-way ANOVA). In contrast, the induction of IFNλ
using an agonist of interferon signaling, Poly(I:C), was intact under nitazoxanide
treatment, demonstrating that the observed response is specific to parasite infection. We
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therefore conclude that live parasites and active parasite replication are required to induce
the type III interferon response.

Figure 4.2 IFN-lambda production requires live infection and is initiated by infected cells
continued on page 102
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Figure 4.2 IFN-lambda production requires live infection and is initiated by infected cells
We examined the requirements and kinetics of initiation of the type III interferon response to C.
parvum. (A) 24 well HCT-8 cultures were infected with 200,000 C. parvum live or heat killed oocysts
and protein levels of IFNλ were assessed by ELISA. At 48 and 72 hours post infection the difference
between live and heat killed was highly significant. Two-way ANOVA with Šídák’s multiple
comparisons test **** p <0.0001. n=3 (B) Immunoblot comparing induction of STAT1
phosphorylation by infection with live versus heat killed parasites. Phospho STAT1 is only detected
in live infection. One representative example of two biological replicates is shown. (C) Following
treatment with nitazoxanide (NTZ), infection is reduced 35-fold as assessed by relative abundance
of C. parvum ribosomal RNA transcripts normalized to host GAPDH. n=3. (D) Protein levels of IFNλ
in HCT-8 infected with C. parvum compared to cultures stimulated with 10μg/mL lipofected
Poly(I:C), both in the presence or absence of nitazoxanide. A decrease in IFNλ protein is observed
only when NTZ is used in infection. One-way ANOVA with Šídák’s multiple comparisons test * p
<0.05. n=3 (E) Schematic of the 12-hour intracellular cycle of C. parvum and outline of a sequencing
experiment to examine transcriptional differences between bystanders and infected cells from the
same culture. (F) Immunofluorescence of HCT-8 infected with Cp Neon (green) at 10 hours post
infection. Hoechst in blue. Scale bar 10μm (G) Flow cytometry dot plot of infected cells showing
green fluorescence and side scatter. Three biological replicates were sorted for Neon positive to
Neon negative comparison. (H) Reads mapped to the Cryptosporidium parvum genome in Neon
negative compared to Neon positive populations. (I) Volcano plot showing differentially expressed
genes between Neon negative (bystander) and Neon positive (infected) HCT-8 at 10 hours post
infection. Genes in red are ISGs as identified by Interferome DB.

IFN-lambda is initially produced by infected cells and signals in an autocrine
manner
The parasite completes its replicative cycle within 12 hours and parasite egress is
accompanied by host cell lysis and the release of intracellular contents, including both
host and parasite molecules (Fig 4.2E). Both intracellular parasite growth, and/or host cell
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lysis could trigger the interferon response. Furthermore, signaling, once initiated, results
in the secretion of interferons, which may act on both producing and surrounding cells in
an auto- as well as paracrine fashion. This amplifies the signal through a feedforward loop
rapidly leading to cytokine from essentially all cells, making it difficult to determine how the
cascade originates.
To determine the cells that initiate the type III interferon response, we infected
HCT-8 with a C. parvum strain marked by expression of tandem Neon green
fluorescent protein (Fig 4.2F). At 10 hours post-infection, and prior to the first parasite
egress, we sorted cells for green fluorescence and isolated Neon positive infected cells
as well as Neon negative bystander cells from the same culture (Fig 4.2G). Three
biologically independent samples were subjected to RNA sequencing for each population.
Flow sorting infected from bystanders was confirmed by examining reads mapped to the
C. parvum transcriptome with a 5.5-fold increase in reads from the Neon positive
population (Fig 4.2H). Infection resulted in significant differences in gene expression with
380 upregulated and 466 downregulated genes (1.5-fold; adjusted p value < 0.05, Fig
4.2I). We noted the induction of IFNL1 and 126 additional ISGs as identified by Interferome
DB (Rusinova et al. 2012). Many of these genes represent a subset of the interferon
signature we observed in our 48-hour RNAseq but the amplitude of expression was lower,
likely a reflection of the early time point and the lack of paracrine amplification.
Importantly, at this timepoint induction of the interferon pathway is exclusive to infected
Neon positive cells. We conclude that the type III interferon response is initiated during
intracellular replication of C. parvum in a cell-intrinsic fashion.

103

Exogenous IFN treatment shows no effect on infection in vitro
Robust production of type III interferons in response to Cryptosporidium infection
was demonstrated in HCT-8 cells. Previous work has shown that interferons could limit C.
parvum in the epithelial cell (Pollok et al. 2001, Barakat et al. 2009, Ferguson et al. 2019).
To evaluate the effect of IFNλ on infection, we first performed invasion assays, as
reduction of invasion has been suggested as a mechanism of action against C. parvum.
HCT-8 cultures were pretreated for 16 hours with IFNλ and IFNγ, following a 1-hour
excystation at 37°C, parasites were allowed to invade at 37°C for 2 hours then they were
fixed but not permeabilized. A 4°C incubation was used as a negative control as parasites
show reduced motility and therefore cannot invade at this temperature. At no
concentration of IFNλ tested, invasion measured was different from untreated controls
(Figure 4.3A). We also saw no effect of IFNγ on invasion. We next evaluated if IFNs had
any effect on the overall infection. HCT-8 were pretreated with IFNβ, IFNγ, or IFNλ for 16
hours prior to infection with Nanoluciferase expressing C. parvum. At 48-hours postinfection, no difference between untreated control or any IFN tested were observed
(Figure 4.3B). Thus, we could not identify an impact of IFN treatment on C. parvum
infection in vitro.
Given the role of IFN signaling in cell death, we assessed cell viability following
IFN treatment using MTT assay. In uninfected cells, IFNβ, IFNγ, and IFNλ all reduced host
cell viability (Fig 4.3C). In infected cells, the effects of IFN treatment were unremarkable
in comparison to the effect of infection itself (Fig 4.3D). Infection resulted in a 50%
decrease in host cell viability. IFN treatment did not significantly reduce viability further
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except in the IFNβ treated cells. We demonstrate that IFNs limit HCT-8 growth but despite
a clear effect on the host cell, we find little support for a role in infection in this system.

Figure 4. 3 IFN treatment in HCT-8 cultures infected with C. parvum
We examined the effects of pretreatment of HCT-8 cultures with all three classes of interferons. (A)
HCT-8 cells were pretreated with the indicated amount of interferon for 16 hours then invasion of
C. parvum was quantified (B) HCT-8 cells were pretreated with the indicated amount of interferon
for 16 hours then infected with C. parvum for 48 hours. Infection assessed by Nanoluciferase assay
(C) MTT assay normalized to untreated, uninfected control. Uninfected HCT-8 were treated with
IFN at the indicated doses for 48 hours. One-way ANOVA with Dunnett’s multiple comparisons test
* p <0.05 ** p <0.01. (D) MTT assay normalized to untreated, uninfected control. HCT-8 were
infected for 48 hours following 16 hours treatment with IFN at the indicated doses. One-way
ANOVA with Dunnett’s multiple comparisons test * p <0.05 *** p <0.001.

105

The type III interferon response is required for early in vivo host defense
To understand the consequences of the type III interferon response on infection,
we turned to an in vivo model of infection that uses a C. parvum strain that was adapted
to mice by continued serial passage (Gullicksrud et al. 2021). First, we asked whether and
when type III interferons are produced in response to C. parvum in vivo. At day 2 post
infection of C57BL/6 mice, we found an average 4-fold increase of Ifnl2/3 transcripts in the
small intestine, and at day 4, the induction was approximately 2-fold. (Fig 4.4A). We also
assessed IFNλ secretion during C. parvum infection using an ELISA from punch biopsies
of the ileum and found similar kinetics. IFNλ secretion was increased at 2 days post
infection and waned below detectable levels after 4 days (Fig 4.4B).
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Figure 4.4 Loss of type III IFN signaling increases susceptibility to Cryptosporidium
infection
We used a mouse model of infection to examine the role of type III interferon in Cryptosporidium
infection in vivo. All mice were infected with mouse adapted C. parvum. (A) C57/BL6 (BL6) mice
were infected with 50,000 C. parvum oocysts and relative abundance of IFNλ transcript is shown
for ileal biopsies of infected mice, 4 mice per day, n=2 (B) BL6 mice were infected with 50,000 C.
parvum oocysts and secreted IFNλ protein from ileal biopsies was assessed by ELISA, 2 mice per
day, n=2 (C) Fecal luminescence measured every two days in BL6 wild type mice, mice lacking the
type I IFN receptor Ifnar-/-, and mice lacking the type III interferon receptor Il28ra-/- following infection
with 50,000 C. parvum. A reduction of 3-fold was observed in Ifnar and an increase of 2.7-fold was
observed with Il28ra. 4 mice per group. Data shown is representative of 3 biological replicates.
(Ifnar: -2.8, -2.9-fold, Il28ra: 2.3, 2.7-fold) n=3 (D) C57/BL6 mice were treated with anti-Ifnλ2/3
antibody or an isotype control daily via intraperitoneal (i.p.) injection and infected. Fecal
luminescence was measured every two days. Representative of two biological replicates. An
increase of 2-fold was observed in each replicate. n=2

Type I and III interferons initiate a similar intracellular signaling cascade but utilize
different receptors, IFNAR for type I and a heterodimer of IFNLR1 and IL10RB for type III.
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We infected C57BL/6 wild-type mice, mice lacking the type I interferon receptor, Ifnar -/-,
and mice lacking the type III interferon receptor, Il28ra -/-, with 50,000 C. parvum oocysts.
Infection was monitored by measuring parasite produced Nanoluciferase from feces
(Vinayak et al. 2015). Surprisingly, loss of the type I interferon receptor consistently
resulted in a 3-fold reduction in shedding when compared to wild-type mice (area under
the curve (AUC), Fig 4.4C). In contrast, loss of type III interferon signaling resulted in an
overall 2.7-fold increase in parasite shedding compared to wild-type mice (AUC, Fig 4.4C).
To further validate this finding independent of mouse mutants, we used antibody-based
depletion. C57BL/6 mice were intraperitoneally injected daily with 20μg of an anti-Ifnλ2/3
antibody and infected with 50,000 C. parvum oocysts. Again, we observed an increase in
parasite shedding of about 2-fold (AUC, Fig 4.4D). We note that histopathology revealed
no baseline differences between WT and Il28ra -/- mice (Fig 4.5). We conclude that type III,
but not type I interferons contribute to the early control of Cryptosporidium in vivo.
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Figure 4.5 BL6 and IL28Ra KO mice exhibit similar baseline and post-infection intestinal
pathology scores
(A) Histology scoring from uninfected BL6 wild type mice and mice lacking the type III interferon
receptor Il28ra-/-. No differences were observed. (B) Histology scoring from BL6 wild type mice and
mice lacking the type III interferon receptor Il28ra-/- infected with 50,000 C. parvum and uninfected
controls. One-way ANOVA with Šídák’s multiple comparisons test * p <0.05 ** p <0.01 *** p <0.001
**** p <0.0001. Differences between uninfected Il28ra-/- mice compared to infection tended to be
more statistically significant than those observed between uninfected and infected BL6 mice.
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Exogenous IFN-lambda treatment protects mice from severe Cryptosporidium
infection
Since mice lacking the type III interferon receptor exhibited an increase in early
susceptibility, we next tested the impact of exogenous administration of IFNλ on
Cryptosporidium infection. We first assessed the production of type III IFN in mice lacking
IFNγ and found that in contrast to wild-type mice, infected Ifng-/- mice showed sustained
IFNλ production (Figure 4.6A). This prolonged IFNλ production coincided with the
extended length of infection in mice lacking IFNγ compared to wild-type mice (Fig 4.6B).
Ifng-/- mice were injected intraperitoneally with daily doses of Ifnλ2 ranging from 0-5μg for
the first three days of infection. As little as 0.1μg per day (the smallest amount tested)
produced a marked reduction in shedding (4.3-fold decrease AUC, Fig .6C), and
increasing the dose beyond 1μg did not yield further enhancement. To assess whether
this effect could be maintained long term, Ifng-/- mice were infected with C. parvum and
injected intraperitoneally with a daily dose of 1μg Ifnλ2 for the duration of the infection.
This treatment resulted in a 7.7-fold reduction of shedding when compared to mock
injected control infections (AUC, Fig 4.6D). In contrast to mock injected mice, we did not
observe mortality among treated mice.
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Figure 4.6 The type III Interferon response is host protective and epithelial cell intrinsic
(A) Ifng-/- mice were infected with 20,000 C. parvum oocysts and secreted IFNλ protein from ileal
biopsies was assessed by ELISA, 2 mice per day, n=1 (B) Same mice as in (A) Fecal luminescence
measured in Ifng-/- mice following C. parvum infection, 2 mice per day, n=1 (C) Ifng-/- mice were
injected i.p. with indicated doses of Ifnλ2 daily for days 0-3 of infection. Mice were infected with
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20,000 C. parvum oocysts. The total area under the curve of fecal luminescence for the 3-day
infection is shown. 2 mice per dose. Representative of 2 biological replicates (0.1μg: 4.3 and 5.9fold; 0.5μg: 7 and 1.3-fold; 1μg: 3.8 and 8.8-fold; 5μg: 7 and 18.6-fold). n=2 (D) Ifng-/- mice were
injected i.p. with 1μg of Ifnλ2 beginning at day 0 and each day for the duration of the infection. Mice
were infected with 20,000 C. parvum oocysts. Fecal luminescence measured every two days. A
7.7-fold decrease in shedding occurred upon treatment representative of 2 biological replicates (5fold decrease) n=2 (E) BL6 wild type mice, mice lacking T cells Rag2-/-, and mice lacking NK cells,
ILCs, and T cells Rag2/Il2rg-/- were treated with 1μg of Ifnλ2 daily for the days 0-3 of infection. The
total area under the curve of fecal luminescence for the 3-day infection is shown. (BL6: 2.4, 1.14,
1.22-fold; Rag2-/- 4.4, 1.8, 16.3-fold; Rag2/Il2rg-/- 2, 3.8, 6.5-fold) Representative of 3 biological
replicates. n=3 (F) BL6 wild type mice and mice lacking Irgm1/m3 were treated with 1 μg of Ifnλ2
daily for for the days 0-3 of infection. The total area under the curve of fecal luminescence for the
3-day infection is shown. Representative of 2 biological 2.3-fold and 2.2-fold(G) Villin Cre STAT1
flox mice or littermate Cre negative controls were treated with 1μg of Ifnλ2 daily for the days 0-3 of
infection. The total area under the curve of fecal luminescence for the 3-day infection is shown.
Representative of 2 biological replicates (Cre negative: 4 and 2.2-fold; Cre positive: 0.85 and 1.14fold) n=2

We note that administration of IFNλ was protective in Ifng -/- mice, suggesting that
this protection does not require IFNγ. However, IFNλ has been shown to promote IFNγ
production (Gimeno Brias et al. 2018). To examine this potential interaction further we
tested the effect of IFNλ in mice lacking cells known to produce IFNγ in response to C.
parvum: T cells, NK cells and ILCs (Culshaw et al. 1997, Barakat et al. 2009, Gullicksrud
et al. 2021). BL6, Rag2-/-, and Rag2-/-Il2rg-/- mice were infected and treated with 1μg of
Ifnλ2. This resulted in a comparable reduction of parasite shedding (BL6: 2.4-fold, Rag2-/: 4.4-fold, Rag2-/-Il2rg-/-: 2-fold, Fig 4.6E), again suggesting that the benefit of IFNλ
treatment does not require immune cells, but largely rests on an enterocyte intrinsic
response. (Fig 4.6F) Additionally, we conducted experiments with mice in which the
STAT1 gene was specifically ablated from enterocytes using Cre recombinase under the
control of the Villin1 promoter. Removing STAT1 from the enterocyte lineage alone
abolished the benefit of IFNλ treatment (1.1-fold AUC, Fig 4.6G). Taken together, these
data suggest that IFNλ protects mice and does so by acting directly on the intestinal
epithelium.
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TLR3 detects Cryptosporidium infection leading to IFN-lambda production
Enterocytes have been shown to use a range of pattern recognition receptors to
detect infection with different pathogens, many of which can lead to a type III interferon
response (Syedbasha and Egli 2017). We recently identified an NLRP6 dependent
inflammasome that is activated in response to Cryptosporidium infection (Sateriale et al.
2021). NLRP6 has been shown to signal through MAVS to induce type I and III IFN
production in response to viral infection (Wang et al. 2015). We measured IFNλ production
in the ileum of infected Nlrp6-/- mice and littermate controls. On day 2 post-infection, no
difference in infection was observed between Nlrp6-/- mice and controls (Fig 4.8A).
Accordingly, no difference in levels of IFNλ production was observed between Nlrp6-/- mice
and controls (Fig 4.8B). We conclude that NLRP6 dependent recognition of
Cryptosporidium is not required for IFNλ production.
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Figure 4.7 NLRP6 dependent recognition of Cryptosporidium is not required for type III IFN
production
We sought to identify the pattern recognition receptor that is activated to induce IFNλ production in
response to Cryptosporidium infection by first examining the known receptor, NLRP6. (A) Infection
of control littermates compared to mice lacking NLRP6. Fecal luminescence measured at day 2
post-infection n=5 mice per group (F) IFNλ protein detected from ileal biopsies of infected littermate
controls compared to Nlrp6-/- at day 2 post-infection. n=5 mice per group

HCT-8 cells, as many other cancer-derived lines, no longer express the full
complement of innate immune recognition and cell death pathways (Qiao et al. 2021), but
the IFNλ response to Cryptosporidium remains intact. We took advantage of this to narrow
the list of potential receptors. HCT-8 cells were treated with known agonists of different
pattern recognition receptors and IFNλ production was measured after 24 hours.
Specifically, we tested Poly(I:C) with or without lipofection (TLR3 and RLRs), mTriDAP
(NOD1 and NOD2), 5’ triphosphate dsRNA (RIGI), HSV60 DNA (CDS), ssPolyU RNA
(TLR7), or CpG motif containing DNA (TLR9) (Broz and Monack 2013). As shown in Fig
4.9A, only Poly(I:C) and ssPolyU RNA produced an IFNλ response. This suggests TLR3,
TLR7, or the RLRs MDA5 and RIGI as potential receptors. We next tested each of these
candidates in vivo using suitable mouse mutants. Mice lacking MAVS, the adapter protein
to RLRs, and TLR7 showed no difference in infection compared to wild type controls (Fig
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4.9B and 4.9C). However, mice lacking TLR3 were more susceptible, resulting in an 8fold increase in parasite shedding and an overall pattern of infection that was reminiscent
of Il28ra-/- mice (AUC, Fig 4.9D). We found the production of IL-18, an enterocyte-derived
cytokine induced by Cryptosporidium infection, (Bedi et al. 2015, Sateriale et al. 2021) to
be intact in the absence of TLR3 (Fig 4.9E). Next, we measured IFNλ secretion from ileal
punches of infected Tlr3 -/- mice and wild-type controls at day 2 of infection by ELISA. In
the absence of TLR3, IFNλ production was reduced to the limit of detection (Fig 4.9F, p
value < 0.001, Unpaired t-test). Note that this reduction occurs despite an 8-fold higher
level of infection in Tlr3-/-. Finally, we generated TLR3 KO HCT-8 cells using CRISPRCas9 directed mutagenesis. Infection of TLR3 KO HCT-8 and Cas9 expressing HCT-8
control cells were comparable at 48 hours post-infection (Fig 4.9G). Despite similar levels
of infection, TLR3 KO HCT-8 cells showed significantly less expression of IFNL1 (p value
< 0.01, Standard t-test, Fig 4.9H). We conclude that the production of type III IFN during
Cryptosporidium infection depends on TLR3 signaling.
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Figure 4.8 TLR3 dependent recognition of Cryptosporidium
We sought to identify the pattern recognition receptor that is activated to induce IFNλ production in
response to Cryptosporidium infection. (A) ELISA of HCT-8 cultures infected with C. parvum or
treated with the indicated agonist for 24 hours to assess IFNλ production in response to stimulus
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against a variety of pattern recognition receptors, n=3. IFNλ is induced in response to the following
stimuli: infection, Poly(I:C), lipofected Poly(I:C), and ssPolyU RNA (B) Infection of wild-type control
mice (B6129) compared to mice lacking MAVS. Fecal luminescence measured every 2 days.
Representative of 2 biological replicates (1.18 and 1.04-fold increase) n=2 (C) Infection of wild type
control mice (C57B6N/J) compared to mice lacking TLR7. Fecal luminescence measured every 2
days. Representative of 3 biological replicates (1.3, 0.70, 2.2-fold increase) n=3 (D) Infection of
wild-type control mice (B6129) compared to mice lacking TLR3. Fecal luminescence measured
every 2 days. An increase of 8-fold in oocyst shedding was observed. Representative of 3 biological
replicates (8, 12.4, 3.8-fold respectively) n=3 (E) IL-18 protein detected from ileal biopsies of
infected mice wild type (B6129) compared to Tlr3-/- at day 2 post-infection. Standard t-test *** p
<0.001. 11 mice per group, n=2 (F) IFNλ protein detected from ileal biopsies of infected mice wild
type (B6129) compared to Tlr3-/- at day 2 post-infection. Standard t-test *** p <0.001. 11 mice per
group, n=2. Dotted line represents the limit of detection. (G) TLR3 KO HCT-8 and Cas9 control cell
line were infected with C. parvum for 48 hours. Relative abundance of C. parvum ribosomal RNA
transcripts normalized to host GAPDH. n=3 (H) same samples as in (G) relative abundance of
IFNL1 in TLR3 KO HCT-8 and Cas9 control cell at 48 hours post-infection. Standard t-test ** p
<0.01 n=3

Discussion
The role of IFNγ in cryptosporidiosis is well established, but there have also been
reports of interferons directly produced by the enterocyte during Cryptosporidium infection.
Barakat et al. described the production of type I interferons in response to C. parvum
infection in a mouse cell line (Barakat et al. 2009). Transcriptional profiling of infected
organoids from the lung and small intestine revealed a signature that was similarly
interpreted as a response to type I IFN signaling (Heo et al. 2018, Nikolaev et al. 2020).
In contrast, Ferguson et al. recently reported type III interferon production in response to
C. parvum infection in neonatal piglets and neonatal mice (Ferguson et al. 2019). Their
studies further suggested that IFNλ may block parasite invasion and promote barrier
integrity during C. parvum infection.
We demonstrate here that Cryptosporidium infection leads to the production and
rapid accumulation of high levels of IFNλ in HCT-8 cultures. Interferons are potent
inducers of cell death programs (Barber 2000, Schmeisser et al. 2014), can arrest the cell
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cycle of target cells, and induce apoptosis, necroptosis, and autophagy (Brand et al. 2005,
Maher et al. 2008, Gao et al. 2014, Jarry et al. 2017). As primary epithelial cells are
terminally differentiated and no longer divide, the role of type III interferons in vivo in
response to Cryptosporidium infection likely involves a form of programmed cell death.
Interferon signaling can activate either apoptosis or necroptosis depending on the
activation state of Caspase-8. The TLR3 adaptor protein TRIF recruits RIPK1 to be
activated to induce necroptosis (Meylan et al. 2004), in the absence of inhibitors of
Caspase-8 this complex can then induce apoptosis (Feoktistova et al. 2011). Induction of
autophagy by interferons was shown to be IRF-1 dependent and led to cell death of
hepatocytes (Li et al. 2012).
In this study, we show pronounced production of type III, but not type I interferons
in human cells (Fig 4.1). We found the response to be initiated intrinsically in the infected
cell (Fig 4.2) and amplified by an autocrine loop. Experiments in vivo demonstrated a
protective role for IFNλ that did not require IFNγ or adaptive immunity but relied on
signaling in enterocytes (Fig 4.6). Further, we discovered the pattern recognition receptor,
TLR3, to be required for type III interferon production. TLR3 recognizes dsRNA, and we
used the synthetic analog Poly (I:C) to induce IFNλ production. Previous studies have
shown that injection of Poly (I:C) reduced C. parvum infection (Lantier et al. 2013).
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Figure 4.9 Model of TLR3 dependent recognition of Cryptosporidium
Cryptosporidium infection leads to sensing by the endosomal pattern recognition receptor TLR3.
Following activation of TLR3, IFNλ transcription is induced. Once IFNλ is secreted, it acts first on
the infected cell (1), and then on uninfected bystanders (2) to induce the transcription of hundreds
of ISGs. Lysis of the host cell by parasite egress releases intracellular contents, including IFNλ,
further amplifying the type III interferon response. The protective effects of IFNλ in mice require
intact STAT1 signaling in the intestinal epithelial cell lineage. One proposed mechanism of action
for IFNλ is to block invasion of the parasite.

TLR3 is known to recognize other protozoan parasites including Neospora (Beiting
et al. 2014) and Leishmania (Ives et al. 2011), where it induces type I IFN production. Of
note, these infections were assessed within macrophages likely why type I IFN was
identified but not type III IFN. For Leishmania, TLR3 recognition was dependent on the
presence of a dsRNA virus found in certain parasite isolates. Interestingly,
Cryptosporidium is also host to a dsRNA viral symbiont which could be a possible source
of dsRNA recognized by TLR3 (Khramtsov et al. 1997, Khramtsov et al. 2000). In contrast
to leishmaniasis where type I IFN production exacerbates disease (de Carvalho et al.
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2019), the type III interferon response to C. parvum is host protective. There have also
been reports of Cryptosporidium derived RNAs being trafficked into the host cell nucleus
during infection providing an additional potential trigger for TLR3 (Wang et al. 2016). While
our screen did not identify TLR3 as a top candidate, UNC93B1, a protein critical to proper
trafficking of endosomal TLRs (Lee et al. 2013), was a highly enriched gene.
Cryptosporidiosis is most dangerous in children below the age of two years and it is thus
noteworthy that TLR3 is poorly expressed in neonates, and that lower levels of TLR3 in
the intestinal epithelium have been linked to the heightened susceptibility of neonatal mice
to rotavirus (Pott et al. 2012).
The increase in parasite burden in mice lacking TLR3 exceeded that of mice
lacking IFNLR1 (8-fold compared to 2.5-fold), potentially pointing towards TLR3 functions
beyond induction of type III interferon in epithelial cells. TLR3 is known to promote crosspriming of CD8+ T cells via DC phagocytosis of virus infected cells (Schulz et al. 2005).
The absence of TLR3 signaling can impair the production of IL-12 by DCs (Kato et al.
2006) which is important for the control of Cryptosporidium infection (Lantier et al. 2013).
We recently reported that an enterocyte intrinsic NLRP6 inflammasome is
activated by Cryptosporidium infection leading to release of IL-18 (Sateriale et al. 2021).
This IL-18 in conjunction with IL-12 then promotes downstream IFNγ production by
ILCs (Gullicksrud et al. 2021). Here we describe a second parasite detection mechanism
that depends on TLR3 and produces a rapid IFNλ response that precedes the production
of IFNγ by NK/ILCs and T cells. IFNλ has been shown to augment the IFNγ response of
NK cells via a mechanism involving IL-12 (Gimeno Brias et al. 2018). Consistent with this
idea treatment of Rag2-/-Il2rg-/- was repeatedly less effective than that of Rag2 -/- alone (Fig
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4G), suggesting a potential role for IFNλ in promoting IFNγ production in NK/ILCs.
However, loss of STAT1 exclusively in the enterocyte lineage led to almost a complete
abrogation of the effects of IFNλ treatment (Fig 4.6G), arguing that the primary role of IFNλ
is to act on the enterocyte. The protective effects of IFNλ treatment even in
immunocompromised mice were striking. Treatment resulted in control in mice that are
extremely susceptible to cryptosporidiosis (Barakat et al. 2009, Gullicksrud et al. 2021)
and

lack central elements of innate

immunocompromised

individuals

and adaptive

suffering

from

immunity. Treatment of

cryptosporidiosis

remains

very

challenging (Hadžić et al. 2019, Huston 2020). Clinical trials for use of pegylated IFNλ
have shown promise for the treatment of viral infections (Phillips et al. 2017, Feld et al.
2021) and its efficacy against Cryptosporidium warrants further study.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
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GPI anchors are required for Cryptosporidium infection
In CHAPTER 3, GPI anchor biosynthesis was highly enriched by our genetic
screen. We hypothesize that GPI anchors provide a structure for attachment and/or
invasion of the parasite. The association of GPI anchors with the apical membrane in
polarized epithelial cells and the enrichment of GPI anchored proteins in microdomains
makes their involvement in the early stages of infection plausible.
We were unable to obtain HCT-8 cell lines with homozygous disruption in the GPI
anchor pathway. This could suggest essentiality but in other cell lines, GPI anchors are
not absolutely required for survival (Ferguson et al. 2009). Mutations in the GPI anchor
pathway may still be detrimental to the HCT-8 cells making their enrichment in the screen
that much more noteworthy. Only when the selection was as strong as survival or host cell
death were we able to obtain numerous cells with targeted disruption in GPI anchor
synthesis.
Another reason for the enrichment of GPI anchor biosynthesis in our screen may
be their role in promoting signaling in microdomains. Src family kinases, integrins, and
non-receptor tyrosine kinases have all been shown to be enriched in microdomains.
Therefore, GPI anchor biosynthesis may play multiple important roles during
Cryptosporidium infection.

Jak inhibitors reduce Cryptosporidium infection
In CHAPTER 3, our screen identified the importance of IFN signaling in
Cryptosporidium infection. Initially, this observation was puzzling; why and how does an
antiviral response promote Cryptosporidium infection? The screen also selected for
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pathways that induce host cell death which we demonstrated occurs in our HCT-8 cultures
in response to IFN stimulation alone. We elucidated a role for type III IFN in parasite
control in vivo. How then does inhibition of TYK2 and JAK1 reduce parasite growth in
vitro?
HCT-8 cells are a cancer cell line, we could simply attribute this phenomenon to a
bad model. The fact that Jak inhibitors reduced infection in C. parvum infected HCT-8 cells
but not T. gondii infected HCT-8 cells suggests there is more to this observation than
peculiarities in the cell line. This observation may support the studies that claim cell death
is required for Cryptosporidium infection because inhibition of the Jaks would presumably
reduce the antiproliferative effects of infection induced IFN. Confirming this observation in
primary epithelial cells would be the first step to evaluate how inhibition of type III IFN
signaling may be detrimental to Cryptosporidium in vitro.

TLR3 and Cryspovirus
In CHAPTER 4 we demonstrated that TLR3 recognizes Cryptosporidium and
induces a type III interferon response to infection. As a dsRNA sensor, TLR3 is typically
activated during viral infections. The endosymbiont, Cryptosporidium parvum virus 1
(CPV1) is a potential source of such dsRNA during infection. There is currently no
evidence that CPV1 is released into the host cell, but the Leishmania endosymbiont,
LRV1, was shown to be released in exosomes (de Carvalho et al. 2019) which could also
play a role in release of CPV1. Exosomes have been shown to be released apically from
epithelial cells infected with Cryptosporidium (Hu et al. 2013). Exosomes released from
infected cells could be profiled for the presence of CPV1 RNA.
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To determine whether CPV1 is sensed by TLR3 we need to eliminate or reduce
the expression of the dsRNAs and assess the impact on infection and type III interferon
production. CPV1 has been found in all isolates of C. parvum and C. hominis, and a virus
free strain is thus not readily available for comparison. Developing a pharmacological or
genetic strategy to selectively target viral replication could yield a key tool to dissect the
role of virus and its dsRNAs have in TLR3 activation – or all other matters of
Cryptosporidium biology and host-parasite interaction.

Long non-coding RNAs as inducers of type III IFN
Another potential infection induced RNA that could be sensed by TLR3 are the
recently characterized parasite lncRNAs targeted to the host cell nucleus. Interestingly,
one of the proteins required for the action of the parasite derived lncRNA in the host cell
is an ISG. PRDM1 or BLIMP-1 is upregulated in our 48-hour RNAseq data, while at
baseline its expression in HCT-8 is low. lncRNA may induce the type III interferon
response to facilitate their suppression of other transcripts. BLIMP-1 is also a negative
regulator of type III interferon signaling allowing the parasite lincRNAs to have a role in
dampening the response.

TRIF independent TLR3 signaling
We observed a greater increase in susceptibility in Tlr3-/- mice compared to
Il28ra-/- (8-fold compared to 2.5-fold). Infection of mice lacking the TLR3 adaptor protein,
TRIF, resembled the Il28ra-/- with a 2-fold increase in infection (Fig 5.1). This may suggest
the importance of a TRIF independent branch of TLR3 signaling during Cryptosporidium
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infection. TLR3 activation was shown to recruit the tyrosine kinase c-Src which alters cell
motility, proliferation, and adhesion (Yamashita et al. 2012). Early, within 4 hours of
dsRNA treatment, cell motility was enhanced but treatment for 24 hours inhibited cell
motility. Interestingly, c-Src is activated and promotes invasion of Cryptosporidium (Chen
et al. 2003). The late effects of TLR3 activation that inhibit cell motility, likely by inhibiting
the nucleation of actin would negatively affect invasion of C. parvum. Potentially
recruitment of c-Src to TLR3 in the endosome may thus also act as a ‘sponge’ reducing
the available pool for Cryptosporidium invasion.

relative luminescence units

A
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TRIF KO

2 4 6 8 10

2 4 6 8 10
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6×105
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days post infection

Figure 5. 1 Mice lacking TRIF phenocopy IL28R KO
(A) Fecal luminescence measured every two days in BL6 wild type mice and Trif-/- mice following
infection with 50,000 C. parvum. An increase of 2-fold was observed in TRIF. 4 mice per group.
n=1

Type III interferons and cell death
Interferon signaling can activate either apoptosis or necroptosis depending on the
activation state of Caspase-8. The TLR3 adaptor protein TRIF recruits RIPK1 to be
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activated to induce necroptosis (Meylan et al. 2004), in the absence of inhibitors of
Caspase-8 this complex can then induce apoptosis (Feoktistova et al. 2011). Although
type III interferons specifically have not been shown to induce necroptosis the response
can be STAT1 dependent (Thapa et al. 2013) indicating the potential for necroptosis
downstream of interferon lambda signaling.
We infected mice lacking components of the necroptosis pathway, RIPK3 and
MLKL. Infection of these mice did not produce striking differences in infection burden (Fig
5.2A). When these mice were treated with exogenous IFNλ, the BL6 control and RIPK3
KO mice were both protected and showed a decrease in infection (Fig 5.2B). Surprisingly
the MLKL KO mice were not protected from infection with exogenous IFNλ treatment in a
manner similar to that observed in the enterocyte specific deletion of STAT1. This
experiment needs to be replicated to examine more rigorously whether necroptosis is in
fact a mechanism of type III IFN induced cell death in Cryptosporidium infection. In this
model we could envision that infection induces necroptosis following TLR3/TRIF signaling
and the production of type III Interferons feeds forward to produce a protective necroptotic
response (Fig 5.2C).
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Figure 5. 2 Necroptosis and type III IFN signaling
(A) Fecal luminescence measured every two days in BL6 wild type mice, Ripk3-/- mice, and Mlkl-/mice following infection with 50,000 C. parvum. An increase of 1.2-fold was observed in Ripk3 and
a decrease of 1.1-fold was observed with Mlkl. 3 mice per group. n=1 (B) BL6 wild type mice, Ripk3/mice, and Mlkl-/- mice were treated with 1μg of Ifnλ2 daily for the days 0-3 of infection. The total
area under the curve of fecal luminescence for the 3-day infection is shown.BL6 2-fold decrease,
Ripk3 2.6-fold decrease, Mlkl 0.9-fold decrease n=1 (C) model of necroptosis induced by type III
interferon signaling and activation of TLR3
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Primary IEC models of infection
The conclusions we obtain from any experiment are limited by the models we use.
Our genetic screen was conducted in a cancer cell line, ideally the candidates identified
should be confirmed by infection of primary cells. Small intestinal enteroid models of
Cryptosporidium infection have shown sustained growth of the parasite and have
observed interferon signaling (Heo et al. 2018, Nikolaev et al. 2020). These models could
allow for study of the mechanism of type III interferons as well as follow-up on other top
screening candidates.
We thus far have been unable to recapitulate the efficient growth of C. parvum in
air liquid interface cultures recently reported (Wilke et al. 2019) with our own data showing
infections at 105 at peak 2-logs less than the levels of 10 7 reported in the publication (Fig
5.3A). Our inability to measure robust parasite growth in air liquid interface cultures has
limited their use to measure the impact of interferons. This may be due to technical
problems or differences in mice or reagents.
We know that the crypts that we isolate from mice produce cells that can be
infected by Cryptosporidium. New development of a mini-gut on a chip system showed
successful completion of the life cycle of Cryptosporidium (Nikolaev et al. 2020). Infection
of mini-guts was successful with obvious growth of parasites as evidenced by sexual
differentiation (Fig 5.3B) The mini-guts are a limiting resource making a standard 2D
culture more attractive for immunological assays that do not require microscopy.
We have isolated small intestinal crypts from the following mice: Il28ra -/-, Tlr3-/-,
Mavs-/-, Tlr7-/-, Mlkl-/-, and Ripk3-/-. These lines will allow us to study the role of type III
interferons in limiting Cryptosporidium infection in primary epithelial cells.
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Figure 5. 3 Small intestinal enteroid models of Cryptosporidium infection
(A) Infection of air liquid interface cultures with 200,000 oocysts yields growth to 96 hours followed
by a drop in infection as measure by qPCR. The data here show infections that are 2-logs lower
infected than observed in Wilke et al with the same infectious dose (B) Mini guts infected with a C.
parvum strain expressing a red fluorescent cytoplasmic marker and a nuclear green fluorescent
protein. We observe sexual differentiation of at 72 hours post infection. Note that female parasites
are brightly labeled red with a single green nucleus. There is also a male gamont centered,
recognizable by its 16 bullet shaped nuclei. Scale bar 5μm
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Concluding Remarks
Our understanding of the host response to Cryptosporidium infection is still
evolving. The genetic screen performed in this work provides an abundance of new host
genes and pathways to explore for their role in Cryptosporidium infection. We also
expanded our knowledge of the importance of type III interferon signaling during infection
by identifying TLR3 as a new pattern recognition receptor of Cryptosporidium infection.
These insights will inform future studies of the intestinal epithelial cell intrinsic immune
response.
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